AUTHOR INDEX

(P = proceedings; S = supplement)

AARSLAND, T. *see* TILL, A. E.
ABBOTT, F. A. *see* PANESAR, S. K.
ABILA, B. & IKUEZE, R. Effects of clemastine, ketotifen and prednisolone on chloroquine pruritus in healthy black Africans, 116P
ABRAMS, S. M. L. *see* KOVACS, I. B.
ADAMS, J. *see* ROLAN, P.
ADAMSON, A. R. *see* HERRICK, A. L.
ADVENIER, C. *see* BRION, N.
AHERNE, G. W. *see* HOSKIN, P. J.
AHMED, J. H., ELLIOTT, H. L., HOWIE, C. A., HOSIE, J. & REID, J. L. Effects of nicardipine on the metabolic responses to food and exercise, 704P
AICARDI, J. *see* LIVINGSTON, J. H.
AJAYI, A. A., BALOGUN, M. O., OYEWO, E. A. & LADIPO, G. O. A. Enalapril in African patients with congestive cardiac failure, 400
AJAYI, A. A. *see* ELLIOTT, H. L.
AL-HABET, S. M. H. & ROGERS, H. J. Methylprednisolone pharmacokinetics after intravenous and oral administration, 285
AL-KHAWAJA, I. *see* HEBER, M. E.
ALLEN, G. D. *see* GILL, T. S.
AL-MUSTAFA, Z. H., WILLIAMS, FAITH, M., HABOUBI, N. Y., MITCHELL, D. M., CHALMERS, R. J. G. & RAWLINS, M. D. Synthesis of methotrexate polyglutamates by human liver *in vivo* in relation to hepatic morphology, 120P
AL-SEREITI, M. R. & TURNER, P. The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP), 159
AL-SEREITI, M. R. & TURNER, P. The interaction between tropicamide 0.01% and timolol 0.5% on intraocular pressure, 698P
AL-WAIZ, M. *see* AYESH, R.
AMARAL DE MOARES, M. E., ARONSON, J. K. & GRAHAME-SMITH, D. G. The pharmacokinetics of intravenous stable strontium in healthy volunteers, 673P
ANTAL, EDWARD J. *see* SWEENEY, KEVIN R.
APPLETON, D. R. *see* FERNER, R. E.
AREZZO, J. C., SCHROEDER, C. E., LITWAK, M. S. & STEWARD, D. L. Effects of vigabatrin on evoked potentials in dogs, 53S
ARNOLD, M. H. *see* PRESTON, SALLY J.
ARONSON, J. K. *see* AMARAL DE MORALES, M. E.
ARONSON, J. K. *see* JENKINS, R.
ARONSON, J. K. *see* WOOD, A. J.
ARZIMANOGLOU, A. *see* LIVINGSTON, J. H.
ASHBY, M. J. *see* BROWN, M. J.
ATTMAN, P. O. *see* EDGAR, B.
ATTWOOD, M. R. Chemical design of cilazapril, 133S
AUBERT, J. F. *see* WAEBER, B.
AURELL, M. *see* EDGAR, B.
AUSTIN, C. A. *see* BURNS, E.
AYESH, R., AL-WAIZ, M., MCBURNEY, A., MITCHELL, S. C., IDLE, J. R., WARD, J. W. & SMITH, R. L. Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine *C* and *N*-oxidative polymorphisms, 423

BACK, D. J. *see* BALL, S. E.
BACK, D. J. *see* MADDEN, S.
BACK, D. J., TJIA, J. F. & BRECKENRIDGE, A. M. Calcium channel antagonists and cyclosporine metabolism, 706P
BACKHOUSE, C. I., BROWN, CHLOE L., GRIPPAT, J. C. & SANTONI, J. PH. Additive antihypertensive effects of perindopril and hydrochlorotiazide: A double-blind parallel group study, 658P
BACON, P. J. BRAZIER, D. J., SMITH, R. & SMITH, S. E. Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers, 1
BAKRAN, A. *see* GUPTA, S. K.
BALDUCCI, F. *see* FERLEY, J. P.
BALOGUN, M. O. *see* AJAYI, A. A.
BALL, C. E. *see* BURNS, E.
BALL, S. E., BACK, D. J. FORRESTER, L., WOLF, C. R. & L'E ORME, M. Differential immunoinhibition of human liver oestradiol and ethinyloestradiol 2-hydroxylase, 644P
BANJAR, W. M. A., BRADSHAW, C. M. & SZABADI, E. Seasonal variation in responsiveness of human eccrine sweat glands to phenylephrine, 276
BANNISTER, R. *see* RAIMBACH, S. J.
BARKER, C. E. & LINDUP, W. E. Effect of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid on the binding of fluorescent probes to human albumin, 675
BARNES, G. R. *see* STOTT, J. R. R.
BARNES, P. J. *see* BUSH, A.
BARNES, P. J. *see* DIXON, CAROLINE M. S.
BARNETT, D. B. Myocardial β-adrenoceptor function and regulation in heart failure: implications for therapy, 529
BARNETT, D. B. *see* FURNISS, J.
BARNETT, J. A., BRENNER, D. E., CREAVEN, P. J. & LALKA, D. Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to α_1-acid glycoprotein (AGP), 257
BARRADA, J. *see* VERNILLET, L.
BARRY, M., KEELING, P. W. N., FEELY, J. Decreased α_1-acid glycoprotein concentration and the plasma protein binding of lignocaine in cirrhosis, 665P
BARRY, M., KELLEHER, P., MULCAHY, F. & FEELY, J. The effect of azidothymidine (AZT) on oxidative drug metabolism in patients with AIDS, 667P
BATEMAN, D. N. *see* ISAH, A. O.
BATEMAN, D. N. *see* LOCKEY, D.
BATHUM, LISE, *see* DROHSE, ANETTE
BAUMGARTNER, H., HORTNAGL, H., FILL, H., LUCKE, G. & STIEGMAYER, A. Adrenaline reaction to

stress: a field study with pilots on capillary and venous adrenaline, 100P
BAX, N. D. S. *see* BURNS, E.
BAYER, A *see* WATT, A. H.
BEASTALL, G. H. *see* LARKIN, J. G.
BEAUMONT, D. *see* BRION, N.
BEAUMONT, D. *see* LIEGEOIS-CHAUVEL, C.
BEAUMONT, D. *see* LIVINGSTON, J. H.
BEAUMONT, D. *see* REMY, C.
BEGG, E. J. *see* GRASBY, P. M.
BEGG, E. J., SHARMAN, J. R., KIDD, J. E., SAINSBURY, R. & CLARK, W. J. Variability in the elimination of mianserin in elderly patients, 445
BELCH, J. J. F. *see* CHOPRA, M.
BELEC, L.., LARREY, D., DE CREMOUX, H., TINEL, M., LOUARN, F., PESSAYRE, D. & GHERARDI, R. Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy, 387
BELLER, ELAINE M. *see* PRESTON, SALLY J.
BELYAVIN, A. J. *see* NICHOLSON, A. N.
BELZ, G. G., ESSIG, J., ERB, K., BREITHAUPT, K., HOOGKAMER, U., KNEER, J. & KLEINBLOESEM, C. H. Pharmacokinetics and pharmacodynamic interactions between the ACE inhibitor cilazapril and β-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients, 317S
BELZ, G. G. *see* ESSIG, J.
BELZ, G. G. *see* KLEINBLOESEM, C. H.
BENJAMIN, N. *see* WEBB, D. J.
BEN-MENACHEM, E. *see* PERSSON, L. I.
BEN-MENACHEM, E., PERSSON, L. I., SCHECHTER, P. J., HAEGELE, K. D., HUEBERT, N., HARDENBERG, J., DAHLGREN, L. & MUMFORD, J. P. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients, 79S
BERG, U. *see* HASSELSTROM, J.
BERGMAN, U. *see* MORTIMER, O.
BERLAND, Y. *see* VERNILLET, L.
BERLAN, M. *see* VALET, P.
BERLIN, I. *see* FLOUVAT, B.
BERTAULT-PERES, P. *see* VERNILLET, L.
BEVAN, J. *see* HEPTINSTALL, S.
BHASKAR, N. K. *see* FELLOWS, I. W.
BHASKAR, N. *see* STEIN, A. G.
BINS, J. W. & MATTIE, H. The tubular excretion of benzylpenicillin in patients with cystic fibrosis, 291
BLACKETT, A. & TURNER, P. Correlation of the partition coefficient with the fragment constant f and the relationship of f to buccal absorption, 123P
BLACKWOOD,, N. *see* THILO, JULIA.
BLANC, M. *see* CALES, P.
BLAUW, G. J., VAN BRUMMELEN, P. & VAN ZWIETEN, P. A. The 5-HT induced biphasic vasodilatation in the human forearm is dose-dependently antagonised by ICS 205-930, 663P
BLOUIN, R. *see* COLANGELO, P.
BODANSKY, J. *see* FEELY, M.
BOGAERT, M. G. *see* LEFEBVRE, R. A.
BOOBIS, A. R., MURRAY, S., GOODERHAM, N. J., & DAVIES, D. S. Systemic exposure to a carcinogenic heterocyclic amine following consumption of meat, 709P
BOOBIS, A. R., SPIERS, C. J., MURRAY, S., MABADEJE, A. F. B. & DAVIES, D. S. Debrisoquine metabolic phenotype in patients with bronchogenic carcinoma, 646P
BORGSTROM, L., NYBERT, L., JONSSON, S., LINDBERG, C. & PAULSON, J. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate, 49
BOTTOMLEY, J. *see* GILL, *see* T. S.
BOULENGER, J. P. *see* GRAM, L. F.
BOUTRY, J. M. *see* HAUW, J. J.
BOWES, S. C. *see* NICHOLSON, P. W.
BOWES, S. G., O'NEILL, C. J. A., DESHMUKH, A. A. LEEMAN, A. L., DOBBS, S. M. & DOBBS, R. J. R. Relevance of pharmacokinetic handling to termination of effect of levodopa in elderly Parkinsonian patients, 123P
BRADSHAW, C. M. *see* BANJAR, W. M. A.
BRADSHAW, C. M. *see* THEOFILOPOULOS, N.
BRATTY, J. R. *see* LEWIS, HELEN M.
BRAWN, L. A. *see* LENNARD, M. S.
BRAZIER,, D. J. *see* BACON, P. J.
BRECKENRIDGE, A. M. *see* BACK, D. J.
BRECKENRIDGE, A. M. *see* IRVIN, L. E.
BRECKENRIDGE, A. M. *see* MILTON, K. A.
BRECKENRIDGE, A. M. *see* WARD, S. A.
BRECKENRIDGE, A. M. *see* WINSTANLEY, P. A.
BREIMER, D. D. *see* SOONS, P. A.
BREIMER, D. D. *see* VAN HARTEN, J.
BREIMER, D. D. *see* VAN HOOGDALEM, E. J.
BREITHAUPT, K. *see* BELZ, G. G.
BREITHAUPT, K. *see* KLEINBLOESEM, C. H.
BRENNER, D. E. *see* BARNETT, J. A.
BRIDGES, A. *see* CHOPRA, M.
BRIGDEN, G. *see* HEBER, M. E.
BRINDLEY, C. J. *see* STUCK, A. E.
BRION, N., NALINE, E., BEAUMONT, D., PAYS, M. & ADVENIER, C. Lack of effect of terfenadine on theophylline pharmacokinetics and metabolism in normal subjects, 391
BRODDE, O. E., DOETSCH, N., MICHEL, M. C., WIRTH, C. & ZERKOWSKI, H. R. Myocardial β_1 and β_2-adrenoceptor alterations in patients with mitral valve disease, 661P
BRODDE, O. E. *see* VAN TITS, L. J. H.
BRODIE, M. J. *see* LARKIN, J. G.
BRODIE, M. J. *see* HERRICK, A. L.
BROOKS, P. M. *see* PRESTON, SALLY J.
BROSEN, KIM. *see* DROHSE, ANETTE
BROUGHTON PIPKIN, F. *see* LOQUET, PH.
BROWN, A. N. *see* MASSARELLA, J. W.
BROWN, A. N. *see* FILLASTRE, J. P.
BROWN, A. N. *see* FRANCIS, R. J.
BROWN, A. N. *see* MASSARELLA, J. W.
BROWN, A. N. *see* WILLIAMS, P. E. O.
BROWN, CHLOE L. *see* BACKHOUSE, C. I.
BROWN, J. *see* FREESTONE, S.
BROWN, K. F. *see* TETT, S. E.
BROWN, M. J., REYNOLDS, D. J. & ASHBY, M. J. Differential actions of clonidine and rilmendine on peripheral α_2-adrenoceptors in man, 687P
BROWN, M. J. *see* SHAWKET, S. A.
BROWN, R.A. *see* MCMURRAY, J. J.
BROWN, R. A. *see* SEIDELIN, P. H.
BROWNE, T. R., MATTSON, R. H., PENRY, J. K., SMITH, D. B., TREIMAN, D. M., WILDER, B. J., BEN-MENACHEM, E., MIKETTA, R. M., SHERRY,

K. M. & SZABO, G. K. A multicentre study of vigabatrin for drug-resistant epilepsy, 95S
BRUCE, M. S. *see* JAMES, J. E.
VAN BRUMMELEN, P. *see* VAN HARTEN, J.
VAN BRUMMELEN, P. *see* BLAUW, G. J.
BRUNNER, H. R. *see* WAEBER, B.
BRUNNER, H. R. *see* BURNIER, M.
BULPITT, C. J. *see* PARR, G.
BUNCH, C. *see* WOOD, A. J.
BURGGRAFF, J. *see* VAN HARTEN, J.
BURKE, J. *see* STEIN, A. G.
BURKE, M. T. *see* HARRON, D. W. G.
BURNIER, M., MOOSER, V., NUSSENBERGER, J., WAEBER, B. & BRUNNER, H. R. Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man, 189S
BURNS, E., AUSTIN, C. A. & BAX, N. D. S. Cognitive assessment and drug information in the elderly, 653P
BURNS, E., BALL, C. E., TRIGER, D. R. & BAX, N. D. S. A two-compartment pharmacokinetic model fails to predict the hepatic extraction ratio of indocyanine green, 705P
BURTON, R. W. *see* PANESAR, S. K.
BURY, R. W. *see* JOHNSON, G. J.
BUSH, A. *see* BUSST, C. M.
BUSH, A., BUSST, C. M., CLARKE, B. & BARNES, P. J. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects, 165
BUSSLINGER, A. *see* STUCK, A. E.
BUSST, C. M. *see* BUSH, A.
BUSST, C. M. & BUSH, A. Comparison of the cardiovascular and pulmonary effects of oral celiprolol and placebo in normal volunteers, 405
BUTLER, E. *see* LARKIN, J. G.
BOLTON, J. B., RIMMER, E., WILLIAMS, J. & RICHENS, A. The effect of vigabatrin on brain and platelet GABA-transaminase activities, 35S

CAILLARD, V. *see* GRAM, L. F.
CALES, P., GRASSET, D., RAVAUD, A., MESKENS, C., BLANC, M., VINEL, J. P. COTONAT, J. & PASCAL, J. P. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension, 690
CALLIECO, R. *see* COSI, V.
CAMPBELL, I. C. *see* WIECK, A.
CHAKRABORTY, J. *see* SCOTT, N. R.
CHALMERS, R. J. G. *see* AL-MUSTAFA, Z. H.
CHANDLER, M. *see* COLANGELO, P.
CHAPMAN, D. *see* HOSKIN, P. J.
CHAPMAN, K. R., GLAKO, B. M., SMITH, D. L. & LEENEN, F. H. H. Effects of atenolol *vs* dilitiazem on the haemodynamic effects of an inhaled β_2-adrenoceptor agonist, 268
CHAPRON, DENNIS J. *see* SWEENEY, KEVIN R.
CHAUVEL, P. *see* LIEGEOIS-CHAUVEL, C.
CHECKLEY, S. A. *see* WIECK, A.
CHOPRA, M., SCOTT, N., MCMURRAY, J., MCCLAY, J., BRES, A., SMITH, W. E. & BELCH, J. J. F. Captopril: a free radical scavenger, 396
CHONG, S. K. F. *see* GORCHEIN, A.
CHOUDRY, N., MCEWAN, J. R. & FULLER, R. W. The effects of sulindac on the cough associated with angiotensin converting enzyme inhibitor therapy, 657P
CHREMOS, A. N. *see* SAMBOL, N. C.
CHRISTMAS, L. *see* SIMPSON, P. M.
CHRISTMAS, L. *see* WESNES, K. A.
CHRYSTYN, H., ELLIS, J. W., MULLEY, B. A. & PEAKE, M. D. Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times, 215
CHRYSTYN, H. *see* KUMAR, S.
CLARK, W. J. *see* BEGG, E. J.
CLARKE, B. *see* BUSH, A.
CLOW, K. W. *see* SURTEES, M.
CLOZEL, J. P. Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats, 167S
CLOZEL, J-P. *see* FISCHLI.
COHEN, A. F. *see* VAN HOOGDALEM, E. J.
COHEN, A. F. *see* VAN STEVENINCK, A. L.
COLANGELO, P., CHANDLER, M., BLOUIN, R. & MCNAMARA, P. Stereoselective binding of propranolol in the elderly, 519
COOPER, S. J., GILLILAND, A., KELLY, C. & MCGILLOWAY, S. The effect of ICI 118,551 in acute anxiety states, 651P
COPELAND, S. *see* PASSMORE, A. P.
CORTELLI, P. *see* RAIMBACH, S. J.
COSI, V., CALLIECO, R., GALIMBERTI, C. A., MANNI, R., TARTARA, A., MUMFORD, J. & PERUCCA, E. Effects of vigabatrin on evoked potentials in epileptic patients, 61S
COTONAT, J. *see* CALES, P.
COUNDOURIS, J. A., GRANT, M. H., ENGESET, J., PETRIE, J. C. & HAWKSWORTH, G. M. Cryopreservation of human adult hepatocytes for toxicity studies, 666P
COURNOT, A. *see* FLOUVAT, B.
COUTIE, W. *see* LIPWORTH, B. J.
COWEN, P. J. *see* GRASBY, P. M.
COWEN, P. J. *see* SOLOMON, R. A.
COX, D. *see* HARRON, D. W. G.
CREAVEN, P. J. *see* BARNETT, J. A.
CROOK, D. *see* DEVENPORT, M. H.
CROSS, N. *see* ROBERTSON, D. R. C.
CROSSMAN, D. C. & FULLER, R. W. Inhibition of tachykinin-induced wheal by sodium cromoglycate in human skin, 710P
CUMIN, F. *see* DE GASPARO, M.
CURRIE, S., LEWIS, R. V., MCLAY, J., TREGASKIS, B. & MCDEVITT, D. G. Relative effects of digoxin and diltiazem upon memory and psychomotor performance in patients with AF, 652P
CURRY, P. V. L. *see* FRANCIS, R. J.
CUTLER, D. J. *see* TETT, S. E.

D'ADHEMAR, D. *see* FERLEY, J. P.
DAHLGREN, L. *see* BEN-MENACHEM, E.
DALLING, R. *see* ELFELLAH, M. S.
DAM, M. *see* MUMFORD, J. P.
DANESHMEND, T. K. *see* STEIN, A. G.
DANHOF, M. *see* VAN HARTEN, J.
DANIELS, S., EDGAR, D. F., STEWART-JONES, J. H. & TURNER, P. Influence of pretreatment with oxy-

buprocaine on pupillary response to phenylephrine in human volunteers, 698P
DAREKAR, B. *see* PARR, G.
DAVIES, B. E. *see* GILL, T. S.
DAVIES, D. S. *see* BOOBIS, A. R.
DAVIES, I. B. *see* SINCLAIR, A. J.
DAWES, J. *see* STIEKEMA, J. C. J.
DAWLING, S. *see* PARK, G. R.
DAY, R. O. *see* TETT,, S. E.
DE BOER, A. G. *see* SOONS, P. A.
DE BOER, A. G. *see* VAN HOOGDALEM, E. J.
DE CREMOUX, H. *see* BELEC, L.
DE MEIJER, P. H. E. M., RUSSEL, F. G. M., VAN LIER, H. J. J. & VAN GINNEKEN, C. A. M. A comparison of three mathematical models to describe the disappearance curves of subcutaneously injected ^{125}I-labelled insulin, 461.
DE MEY, C. *see* HANSEN-SCHMIDT, S.
DE MEY, C., MEINEKE, I., ENTERLING, D. & WESCHE, H. Galenic aspects in the assessment of the effect of antacids on the bioavailability of cimetidine, 677P
DE NOORD, O. E. *see* JONKMAN, J. H. G.
DE VANE, P. J. *see* WHYTE, K. F.
DEAN, S. *see* HALL, C. L.
DEBRUYNE, D. *see* GRAM, L. F.
DEFEO, T. *see* MASSARELLA, J.
DEERING, A. H. *see* HARRON, D. W. G.
DENNIS, M. J. *see* LI KAM, T. C.
DENNIS, M. J. *see* OLIVER, K. S.
DENNIS, M. J. *see* SURTEES, M.
DESHMUKH, A. A. *see* BOWES, S. G.
DESHMUKH, A. A. *see* NICHOLSON, P. W.
DEVENPORT, M. H., CROOK, D., WYNN, V. & LEES, L. J. Metabolic effects of low dose fluconazole in healthy female users and non-users of oral contraceptives, 693
DEVISSAGUET, J. P. *see* MACFAYDEN, R. J.
DICKERSON, C. *see* SHAWKET, S. A.
DICKINS, J. *see* NICHOLSON, P. W.
DICKSTEIN, K. *see* TILL, A. E.
DIETRICH, B., KLEINBLOESEM, C. H. & HERRMANN, W. M. Influence of cilazapril on memory functions and sleep behaviour in comparison with metoprolol and placebo in healthy subjects, 249S
DIXON, CAROLINE M. S. & BARNES, PETER J. Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate, 688
DIXON, J. S. *see* SHELLEY, MARIE P.
DOBBS, R. J. *see* BOWES, S. G.
DOBBS, R. J. *see* NICHOLSON, P. W.
DOBBS, S. M. *see* BOWES, S. G.
DOBBS, S. M. *see* NICHOLSON, P. W.
DOETSCH, N. *see* BRODDE, O. E.
DOLLERY, C. T. *see* WARREN, J. B.
DOORENBOS, C. J. & VAN BRUMMELEN, P. The effect of aute ACE inhibition on atrial natriuretic peptide, 243S
DOW, R. J. *see* MACDONALD, F. C.
DOW, R. J. *see* MACLEAN, D.
DROHSE, ANETTE., BATHUM, LISE, BROSEN, KIM & GRAM, L. F. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark, 622
DUCHIER, J. *see* FLOUVAT, B.
DULIE, E. B. *see* MCVEIGH, G. E.
DUNDEE, J. W. & MILLIGAN, K. R. Induction dose of thiopentone: the effect of alcohol intake, 693P
DURAND, A. *see* VERNILLET, L.
DURNIN, C. *see* WILLIAMS, P. E. O.
DURRIEU, G. *see* VALET, P.
DUYCKAERTS, C. *see* HAUW, J. J.

ECKERT, M. *see* JONKMAN, J. H. G.
EDGAR, B., REGARDH, C. G., ATTMAN, P. O., AURELL, M., HERLITZ, H. & JOHNSSON, G. Pharmacokinetics of felodipine in patients with impaired renal function, 67
EDGAR, D. F. *see* WRIGHT, S.
EDGAR, D. F. *see* DANIELS, S.
EDVINSSON, L. *see* OTTOSSON, A.
EDWARDS, G. *see* MILTON, K. A.
EDWARDS, G. *see* WINSTANLEY, P. A.
ELFALLAH, M.S., DALLING, R., KANTOLA, I. M. & REID, J. L. β-adrenoceptors and human skeletal muscle characterisation of receptor subtype and effect of age, 31
ELLIOTT, H. L. *see* AHMED, J. H.
ELLIOTT, H. L., AJAYI, A. A. & REID, J. L. The influence of cilazapril on indices of autonomic function in normotensives and hypertensives, 303S
ELLIOTT, H. L. *see* MACDONALD, N. J.
ELLIOTT, H. L. *see* MEREDITH, P. A.
ELLIOTT, H. L. *see* MILLER, S. H. K.
ELLIOTT, H. L. *see* SCHAFERS, R. F.
ELLIS, F. R. *see* SIMPSON, . H.
ELLIS, J. W. *see* CHRYSTYN, H.
ENGESET, J. *see* COUNDOURIS, J. A.
ENTERLING, D. *see* DE MEY, C.
ERB, K. *see* KLEINBLOESEM, C. H.
ERB, K. *see* BELZ, G. G.
ERIKSSON, P. *see* PERSSON, L. I.
ESSIG, J., BELZ, G. G. & WELLSTEIN, A. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril, 217S
ESSIG, J. *see* BELZ, G. G.
ESSIG, J. *see* KLEINBLOESEM, C. H.
EVANS, J. M. *see* SILKE, B.
EVEREST, H. *see* ROBERTSON, D. R. C.

FACCHINI, V. *see* SURTEES, M.
FARRELL, K. *see* PANESAR, S. K.
FARROW, P. R. *see* JONKMAN, J. H. G.
FEELY, J. *see* BARRY, M.
FEELY, M. *see* KUMAR, S.
FEELY, M., PRICE, D., BODANSKY, J. & TINDALL, H. Use of pharmacological indicator to assess compliance with drug therapy in patients with poorly-controlled type II diabetes, 101P
FELLOWS, A. *see* SANDLER, D. A.
FELLOWS, I. W., BHASKAR, N. K. & HAWKEY, C. J. Nature and time course of piroxicam induced injury to gastric mucosa in man, 704P
FERGUSON, D. R. *see* LEWIS, N. P.
FERLEY, J. P., ZMIROU, D., D'ADHEMAR, D., BALDUCCI, F. A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like symptoms, 329
FERNER, R. E., GEORGE, G. & APPLETON, D. R.

Analysis of concentration ratios in paired experiments, 676P

FERNER, R. E., WILLIAMS, F. M., GRAHAM, M. & RAWLINS, M. D. The metabolic effects of aspirin in fasting and fed subjects, 104P

FERNER, R. E., WILSON, D., PATERSON, J. R., WILKINSON, R. & RAWLINS, M. D. The effects of intradermal bradykinin are potentiated by angiotensin-converting enzyme inhibitors in hypertensive patients, 337

FILL, H. *see* BAUMGARTNER, H.

FILLASTRE, J. P., MOULIN, B., GODIN, M., WILLIAMS, P. E. O., BROWN, A. N., FRANCIS, R. J., PINTA, P. & MANFRED, R. Pharmacokinetics of cilazapril in patients with renal failure, 275S

FILSHIE, J. *see* HOSKIN, P. J.

FINCH, M. B. & JOHNSTON, G. D. The effect of tiapamil on peripheral haemodynamics, cardiac conduction, and plasma noradrenaline levels in healthy man, 696P

FINDLYE, L. *see* THILO, JULIA

FIRTH, J. L. *see* KENDALL, D. A.

FISCHLI, W., HEFTI, FRIDOLIN, CLOZEL, J-P. Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats, 151S

FLETCHER, A. *see* PARR, G.

FLOUVAT, B., BERLIN, I., COURNOT, A., ROBINET, D., DUCHIER, J., SARMINI, H. & ROSSI, A. Pharmacokinetic and pharmacodynamic comparison of two doses of the long acting propranolol (80 to 160 mg) in healthy subjects, 541

FORD, J. M. *see* FORSYTH, D. R.

FORRESTER, L. *see* BALL, S. E.

FORSYTH, D. R., MORGAN, R., TRUMAN, C. A., FORD, J. M., WILCOCK, G. K. & ROBERTS, C. J. C. Pharmacokinetics of tacrine hydrochloride in patients with dementia, 674

FOWLER, CHRISTINE. *see* RICHARDS, R.

FOWLES, S. E. & PIERCE, D. M. H.p.l.c. method for the determination of BRL 39123 in human plasma and urine, 111P

FRANCIS, R. J., BROWN, A. N., RAJAGURU, S., WILLIAMS, P. E. O., STEINER, J. & CURRY, P. V. L. A pharmacokinetic study of cilazapril in patients with congestive heart failure, 267S

FRANCIS, R. J. *see* FILLASTRE, J. P.

FRANCIS, R. J. *see* MEREDITH, P. A.

FRANCIS, R. J. *see* WILLIAMS, P. E. O.

FRASER, M. *see* RENONDIN, J-C.

FREESTONE, S., MACDONALD, T. M., JEFFREY, F. F., BROWN, J. & LEE, M. R. The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride, 13

FREY, F. J. *see* STUCK, A. E.

FRISK-HOLMBERG, M., KERTH, P. & MEYER, PH. Effect of food on the absorption of vigabatrin, 23S

FRISTON, K. J. *see* SOLOMON, R. A.

FULLER, R. W. *see* CHOUDRY, N.

FULLER, R. W. *see* CROSSMAN, P. C.

FULLINFAW, R. O. *see* JOHNSON, G. J.

FUNCK-BRETANO, C., KROEMER, H. K., PAVLOU, H., WOOSLEY, R. L. & RODEN, D. M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect, 435

FURNISS, J., MISTRY, R. & BARNETT, D. B. ADP induced fibrinogen receptor exposure on human platelets during the menstrual cycle, 681P

GALIMBERTI, C. A. *see* COSI, V.

GALLOWAY, D. B. *see* MCVEIGH, G. E.

GANTEN, D. *see* LINDPAINTER, K.

GARNER, S. T. *see* HAWKEY, C. J.

GARNER, S. T. *see* SANDLER, D. A.

GARTSIDE, S. E. *see* GRASBY, P. M.

GASIC, S., HEINZ, G., KLEINBLOESEM, C. & KORN, A. Effects of ACE-inhibition with cilazapril on splanchnic and systemic haemodynamics in man, 225S

DE GASPARO, M., CUMIN, F., NUSSENBERGER, J., GUYENNE, T. T., WOOD, J. M. & MENARD, J. Pharmacological investigations of a new renin inhibitor in normal sodium-restricted volunteers, 589

GEORGE, G. *see* FERNER, R. E.

GEORGE, C. F. *see* ROBERTSON, D. R. C.

GEORGE, C. F. *see* GIBBS, SHARON

GIBBS, SHARON, WATERS, W. E. & GEORGE, C. F. The benefits of prescription information leaflets (1), 699

GILL, T. S., HOPKINS, K. J., BOTTOMLEY, J., GUPTA, S. K. & ROWLAND, M. Cimetidine-nicoumalone interaction in man: sterochemical considerations, 469

GILL, T. S., KARRAN, M. A., DAVIES, B. E., ALLEN, G. D. & TASKER, T. C. G. Lack of an effect of atenolol on the stereochemical pharmacokinetics of cromakalim, in healthy male subjects, 112P

GILLILAND, A. *see* COOPER, S. J.

GILLES, H. M. *see* WARD, S. A.

GISSELBRECHT, D. *see* LIEGEOIS-CHAUVEL, C.

GLAKO, B. M. *see* CHAPMAN, K. R.

GLOVER, D. R. *see* HALL, C. L.

GODIN, M. *see* FILLASTER, J. P.

GOLDBERG, A. *see* HERRICK, A. L.

GOMEZ, H. J. *see* TILL, A. E.

GOODERHAM, N. J. *see* BOOBIS, A. R.

GORA, N. P. *see* STEIN, C. M.

GORCHEIN, A., CHONG, S. K. F. & MOWAT, A. P. Oral activated charcoal in protoporphyria with liver damage, 703P

GOROG, P. *see* KOVACS, I. B.

GOTOH, E. *see* SHIONOIRI, H.

GOUGH, K. J. *see* MACDONALD, F. C.

GOUGH, K. J. *see* MACLEAN, D.

GRAHAM, B. R. *see* TOMLINSON, B.

GRAHAM, D. Neuropathology of vigabatrin, 43S

GRAHAME-SMITH, D. G. *see* AMARAL DE MORAES, M. E.

GRAHAME-SMITH, D. G. *see* WOOD, A. J.

GRAHAM, M. *see* FERNER, R. E.

GRAM, L. F., DEBRUYNE, D., CAILLARD, V., BOULENGER, J. P., LACOTTE, J., MOULIN, M. & ZAIFAN, E. Substantial rise in sparteine metabolic ratio during haloperidol treatment, 272

GRAM, L. F. *see* DROHSE, ANETTE

GRAM, L., LARSSON, O. M., JOHSEN, A. & SCHOUSBOE, A. Experimental studies of the influence of vigabatrin on the GABA system, 13S

GRANT, M. H. *see* COUNDOURIS, J. A.

GRASBY, P. M., BEGG, E. J., GARTSIDE, S. E. &

COWEN, P. J. α_2-adrenoceptor antagonism increases nocturnal plasma melatonin in man, 649
GRASMEIJER, G. *see* JONKMAN, J. H. G.
GRASSET, D. *see* CALES, P.
GRAY, C. M. *see* THEOFILOPOULOS, N.
GREAVES, M. W. *see* MALLET, A. I.
GREENWOOD, M. *see* THILO, JULIA
GREGORY, JANET. *see* LAI, C. K. W.
GREGG, H. *see* TILL, A. E.
GREGG, H. *see* TILL, A. E.
GRIPPAT, J. C. *see* BACKHOUSE, C. I.
GROSSE-WILDE, H. *see* VAN TITS, L. J. H.
GRYNNE, B. *see* NILSEN, O. G.
GUENTERT, T. W. *see* JONKMAN, J. H. G.
GUPTA, S. K., BAKRAN, A., JOHNSON, R. W. G. & ROWLAND, M. Cyclosporin-erythromycin interaction in renal transplant patients, 475
GUPTA, S. K. *see* GILL, T. S.
GUPTA, S. K., BAKRAN, A., JOHNSON, R. W. G. & ROWAND, M. Pharmacokinetics of cyclosporin: influence of rateduration profile of an intravenous infusion in renal transplant patients, 353
GUYENNE, T. T. *see* DE GASPARO, M.

HABOUBI, N. Y. *see* AL-MUSTAFA, Z. H.
HAEGELE, K. D. *see* BEN-MENACHEM, E.
HALL, C. L., DEAN, S., KALINOWSKI, S. Z., SMART, W. M. & GLOVER, D. R. Enalapril and atenolol monotherapy compared in 172 essential hypertensive patients, 115P
HALONEN, T. *see* REIKKINEN, P. J.
HAMILTON, A. R. *see* PRESCOTT, L. F.
HANKS, G. W. *see* HOSKIN, P. J.
HANSEN-SCHMIDT, S. & DE MEY, C. Prolonged i.v.-infusion of sorbitol: a tool in clinical pharmacology, 113P
HAPPEL, M. *see* VAN TITS, L. J. H.
HARDENBERG, J. *see* BEN-MENACHEN, E.
HARRIGAN, J. R., HUGHES, D. M. & MEREDITH, P. A. Characteristic inter-species differences in ACE inhibition, 656P
HARRON, D. W. G., DEERING, A. H., SCOTT, M., MCMAHON, M. & SHANKS, R. G. Effect of the combination of alinidine and other anti-anginal drugs on heart rate and blood pressure in healthy volunteers, 23
HARRON, D. W. G. *see* MCKAIGUE, J. P.
HARRON, D. W. G., MCKAIGUE, J. P., BURKE, M. T., RIDDELL, J. G., SHANKS, R. G. & COX, D. Effects of intravenous and oral UK-52,046, an α_1-adrenoceptor antagonist, on heart rate and blood pressure in man, 680P
HARRY, J. *see* ORME, M.
VAN HARTEN, J., BURGGRAAF, J., DANHOF, M., VAN BRUMMELEN, P. & BREIMER, D. D. The contribution of nisoldipine-induced changes in liver blood flow to its pharmackinetics after oral administration, 583
HASSELSTROM, J., BERG, U., LOFGREN, A. & SAWE, J. Long lasting respiratory depression induced by morphine-6-glucuronide? 515
HAUW, J. J., BOUTRY, J. M., SUN, P., SAZDOVITCH, V. & DUYCKAERTS, C. Effects of vigabatrin and of GABA on myelinated rat cerebellar cultures: prelinary data, 47S
HAWKSWORTH, G. M. *see* COUNDOURIS, J. A.
HAWKEY, C. J., HODGSON, S. E., GARNER, S. T. & NORN, A. J. Reactive pharmacy intervention: potential medical impact of prescribing errors, 118P
HAWKEY, C. J. *see* FELLOWS, I. W.
HAWKEY, C. J. *see* STEIN, A. G.
HAZELMAN, B. *see* SHAWKET, S. A.
HEAGERTY, A. M. & SWALES, J. D. A double-blind randomized cross-over study of the efficacy and tolerability of nifedipine and nitrendipine in the treatment of moderate to mild hypertension, 411
HEBER, M. E., BRIGDEN, G., AL-KHAWAJA, I. & RAFTERY, E. B. 24h blood pressure control with the once daily calcium antagonist, amlodipine, 359
HEDGES, A. *see* MAKEDOU, A.
HEFTI, FRIDOLIN *see* FISCHLI, W.
HEIM, J. *see* MERKI, H. S.
HEINZ, G. *see* GASIC, S.
HENDERSON, A. H. *see* HOGAN, J. C.
HEPTINSTALL, S., BEVAN, J., HAWKINS, M. & SANDLER, D. A. Measurements of platelet aggregation in a clinical study of ketanserin in peripheral vascular disease, 122P
HEPTINSTALL, S. *see* MURPHY, J. J.
HERLITZ, H. *see* EDGAR, B.
HERRICK, A. L., MCCOLL, K. E. L., MOORE, M. R., BRODIE, M. J., ADAMSON, A. R. & GOLDBERG, A. Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity, 491
HERRMANN, W. M. *see* DEITRICH, B.
HEYWORTH, R. *see* PRESCOTT, L. F.
HICHENS, M. *see* TILL, A. E.
HIRST, A. D. *see* WIECK, A.
HOBSON, S. *see* ORME, M.
HODGSON, S. E. *see* HAWKEY, C. J.
HOGAN, J. C., LEWIS, M. J. & HENDERSON, A. H. Glyceryl trinitrate and platelet aggregation effects of *N*-acetylcysteine, 619
HOLGATE, S. T. *see* LAI, C. K. W.
HOLGATE, S. T. *see* RICHARDS, R.
HOOGKAMER, J. F. W. *see* KIRCH, W.
HOOGKAMER, J. F. W. *see* BELZ, G. G.
HOPKINS, K. J. *see* GILL, T. S.
HORN, E. H. & RUBIN, P. C. Influence of platelet count on cystolic free calcium measurements in human platelets, 118P
HORTNAGL, H. *see* BAUMGARTNER, H.
HORTON, R. W. *see* THILO, JULIA.
HOSIE, J. *see* AHMED, J. H.
HOSKIN, P. J., HANKS, G. W., AHERNE, G. W., CHAPMAN, D., LITTLETON, P. & FILSHIE, J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers, 499
HOWELLS, R. E. *see* WARD, S. A.
HOWICK, A. *see* THILO, JULIA
HOWIE, C. A. *see* AHMED, J. H.
HOWIE, C. A. *see* MACDONALD, N. J.
HOWIE, C. A. *see* SCHAFERS, R. F.
HUEBERT, N. *see* BEN-MENACHEM, E.
HUGHES, A. D. *see* THOM, S.
HUGHES, D. M. *see* HARRIGAN, J. R.

HUSSEIN, S. *see* MANSOR, S. M.
HUYSMANS, F. TH. M. *see* KLOKE, H. J.

IDLE, J. R. *see* AYESH, R.
IKUEZE, R. *see* ABILA, B.
IRVIN, L. E., WINSTANLEY, P. A., SMITH, J. C., L'E ORME, M. & BRECKENRIDGE, A. M. Adverse drug reaction reports in the Royal Liverpool Hospital 1985–1988, 711P
ISAH, A. O., WILLIAMS, F. M., NICHOLSON, E. & RAWLINS, M. D. Plasma esterase activity of Nigerians in Nigeria and in the United Kingdom, 121P
ISAH, A. O., BATEMAN, D. N. & RAWLINS, M. D. Pharmacodynamic effects of a single intravenous and oral dose of prochlorperazine in young healthy volunteers, 107P
ISHII, M. *see* SHIONOIRI, H.
IYUN, A. O. *see* LENNARD, M. S.

JACKSON, P. R. *see* LENNARD, M. S.
JACKSON, P. R. & TUCKER, G. T. An optimal function for fitting drug concentration-time data? 664P
JACKSON, S. H. D. *see* LI KAM, T. C.
JACKSON, S. H. D. *see* MAKEDOU, A.
JAEGER, R. *see* SAGER, G.
JAHN, G. *see* LI KAM, T. C.
JAMALUDIN, A. *see* MANSOR, S. M.
JAMES, J. E., BRUCE, M. S., LADER, M. H. & SCOTT, B. R. Self-report reliability and symptomatology of habitual caffeine consumption, 507
JAMIESON, M. J. *see* MAKEDOU, A.
JANSEN, I. *see* OTTOSSON, A.
JEFFREY, R. G. *see* FREESTONE, S.
JEFFERS, T. A. *see* WEBSTER, J.
JEFFREY, R. F. *see* MACDONALD, T. M.
JENKINS, R., & ARONSON, J. K. The effects of lithium on Na/K pump numbers and activity in isolated human lymphocytes *in vitro*, 654P
JESSUP, C. L., JESSUP, R., STARK, R. D. & WILLIAMS, C. ICI 192605 a potent, selective thromboxane receptor antagonist is orally active in man, 710P
JESSUP, R. *see* JESSUP, C. L.
JIN, M. *see* LINDPAINTER, K.
JOHSEN, A. *see* GRAM, L.
JOHNSON, R. W. G. *see* GUPTA, S. K.
JOHNSON, G. J., KILPATRICK, C. J., BURY, R. W., FULLINFAW, R. O. & MOULDS, R. F. W. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate – the predictive value of plasma albumin concentration, 633
JOHNSSON, G. *see* EDGAR, B.
JOHNSTON, A. *see* SALEH, S.
JOHNSTON, G. D. & PASSMORE, A. P. The effects of cilazapril alone and in combination with frusemide in healthy subjects, 235S
JOHNSTON, G. D. *see* FINCH, M. B.
JOHNSTON, G. D. *see* MCVEIGH, G. E.
JOHNSTON, G. D. *see* PASSMORE, A. P.
JOHNSTON, G. D. *see* WHITEHEAD, E. M.
JOINER, I. M. *see* WESNES, K. A.
JONKMAN, J. H. G., NICHOLSON, K. G., FARROW, P. R., ECKERT, M., GRASMEIJER, G., OOSTERHIUS, B., DE NOORD, O. E. & GUENTERT, T. W. Effects of α-interferon on theophylline pharmacokinetics and metabolism, 679
JONSSON, S. *see* BORGSTROM, L.
JOYCE, P. W., MILLS, K. B., RICHARDSON, T. & MAWER, G. E. Equivalence of conventional and sustained release oral dosage formulations of acetazolamide in primary open angle glaucoma, 599
JUILLERAT-JEANNERET, L. *see* WAEBER, B.

KAARTTINEN, A. *see* KOULU, M.
KALINOWSKI, S. Z. *see* HALL, C. L.
KALLIO, J. *see* KOULU, M.
KANTOLA, I. M. *see* ELFELLAH, M. S.
KARRAN, M. A. *see* GILL, T. S.
KASSAHUN, K. *see* PANESAR, S. K.
KAUFMANN, D. *see* MERKI, H. S.
KEELING, P. W. N. *see* BARRY, M.
KELLEHER, P. *see* BARRY, M.
KELLY, C. *see* COOPER, S. J.
KELLY, J. G. *see* THOMSON, A. H.
KELMAN, A. *see* WHYTE, K. F.
KEMPF, M. *see* MERKI, H. S.
KENDALL, D. A. & FIRTH, J. L. Adenosine inhibits histamine-stimulated inositol phospholipid hydrolysis in human cerebral cortex slices, 108P
KENDALL, M. J. *see* LEWIS, HELEN M.
KENNY, R. *see* NOLAN, L.
KERR, D. & MACDONALD, I. A. Effects of ethanol on the responses to insulin-induced hypoglycaemia in non-diabetic subjects, 103P
KERTH, P. *see* FRISK-HOLMBERG, M.
KHALIFA, A. M. *see* VAN TITS, L. J. H.
KIDD, J. E. *see* BEGG, E. J.
KILPATRICK, C. J. *see* JOHNSON, G. J.
KIRCH, W. *see* LINDE, M.
KIRCH, W., STROEMER, K., HOOGKAMER, J. F. W. & KLEINBLOESEM, C. H. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril, 297S
KITTERINGHAM, N. R. *see* RILEY, R. J.
KLEINBLOESEM, C. H. *see* DIETRICH, B.
KLEINBLOESEM, C. H., ERB, K., ESSIG, J., BREITHAUPT, K. & BELZ, G. G. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and hypertensive patients, 309S
KLEINBLOESEM, C. H. *see* BELZ, G. G.
KLEINBLOESEM, C. *see* GASIC, S.
KLEINBLOESEM, C. H. *see* KIRCH, W.
KLEINBLOESEM, C. H. *see* KLOKE, H. J.
KLEINBLOESEM, C. H. *see* NILSEN, O. G.
KLOKE, H. J., HUYSMANS, F. TH. M., WETZELS, J. F. M., SLUITER, H. E., FLEINBLOESEM, C. H. & KOENE, R. A. P. Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure, 289S
KNEER, J. *see* BELZ, G. G.
KOECH, D. K. *see* WARD, S. A.
KOENE, R. A. P. *see* KLOKE, H. J.
KOFI EKUE, J. M. *see* WINSTANLEY, P. A.
KOONER, J. S. *see* RAIMBACH, S. J.
KORN, A. *see* GASIC, S.
KOULU, M., SCHEINEN, M., KAARTTINEN, A., KALLIO, J., PYYKKO, K., VUORINEN, J. & ZIMMER, R. H.

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers, 243

KOVACS, I. B., RIDLER, C. D., ABRAMS, S. M. L. & GOROG, P. Effect of tissue-type plasminogen activator in haemostasis. Coagulation and thrombosis: an *in vitro* study from native blood, 690P

KRAMER, PAUL A. *see* SWEENEY, KEVIN R.

KROEMER, H. K. *see* FUNCK-BRENTANO, C.

KUMAR, A. *see* MANSOR, S. M.

KUMAR, R. *see* WIECK, A.

KUMAR, S., PULLAR, T., CHRYSTYN, H., PEAKER, S. & FEELY, M. Prediction of steady-state phenobarbitone levels from measurements after a single dose, 645P

LACOTTE, J. *see* GRAM, L. F.

LACOURCIERE, Y. & PROVENCHER, P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension, 371

LADER, M. H. *see* JAMES, J. E.

LADIPO, G. O. A. *see* AJAYI, A. A.

LAI, C. K. W., GREGORY, JANET & HOLGATE, S. T. Effect of inhaled mast cell stabiliser, *N*-acetylaspartyl-glutamate (Zy15109) on allergen-induced immediate bronchoconstriction, 628

LAING, E. M. T. *see* MACLEAN, D.

LALKA, D. *see* BARNETT, J. A.

LAMBERT, C. *see* RILEY, R. J.

LARKIN, J. G., MCLELLAN, A., MUNDAY, A., SUTHERLAND, M., BUTLER, E. & BRODIE, M. J. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects, 313

LARKIN, J. G., MACPEE, G. J. A., BEASTALL, G. H. & BRODIE, M. J. Effects of anti-epileptic drugs on thyroid hormones, 668P

LARREY, D. *see* BELEC, L.

LARSSON, O. M. *see* GRAM, L.

LAURELL, H. *see* MORTIMER, O.

LAURENCE, D. R. Ethics and the law in clinical pharmacology, 684

LAWRENCE, K. M. *see* THILO, JULIA

LAWSON, M. *see* LI KAM, T.C.

LEARY, W. P. P. *see* OLIVER, K. S.

LEE, M. R.*see* FREESTONE, S.

LEE, M. R. *see* MACDONALD, T. M.

LEEMAN, A. L. *see* BOWES, S. G.

LEENEN, F. H. H. *see* CHAPMAN, K. R.

LEES, K. R. *see* MACFAYDEN, R. J.

LEES, L. J. *see* DEVENPORT, M. H.

LEFEBVRE, R. A., BOGAERT, M. G., TEIRLYNCK, O. & SIOUFI, A. Influence of exercise on plasma nitroglycerin concentrations after transdermal application, 653P

LEIGH, P. N. *see* THILO, JULIA.

LENNARD, M. S., LEWIS, R. V., BRAWN, L. A., TUCKER, G. T., RAMSAY, L. E., JACKSON, P. R. & WOODS, H. F. Timolol metabolism and debrisoquine oxidation polymorphism: a population study, 429

LENNARD, M. S., TUCKER, G. T., WOODS, H. F., SILAS, J. H. & IYUN, A. O. Stereoselective metabolism of metoprolol in Caucasians and Nigerians – relationship to debrisoquine oxidation phenotype, 615

LEWIS, HELEN M., KENDALL, M. J., SMITH, S. R. & BRATTY, J. R. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers, 549

LEWIS, M. J. *see* HOGAN, J. C.

LEWIS, N. P. & FERGUSON, D. R. The effect of enalapril on the renal response to tilting in humans, 191

LEWIS, R. V. *see* CURRIE, D.

LEWIS, R., TREGASKIS, B., MCCLAY, J., SERVICE, E. & MCDEVITT, D. G. Magnesium replacement reduces ventricular ectopy in digitalised patients with atrial fibrillation, 103P

LEWIS, R. V. *see* LENNARD, M. S.

LIEGEOIS-CHAUVEL, C., MARQUIS, P., GISSELBRECHT, D., PANTIERI, R., BEAUMONT, D. & CHAUVEL, P. Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients, 69S

LI KAM WA, T. C., JACKSON, S. H. D., LAWSON, M., DENNIS, M. J. & JAHN, G. Prochlorperazine and its sulphoxide metabolite – simultaneous pharmacokinetic modelling, 669P

LI KAM WA, T. C. *see* MAKEDOU, A.

LIMJUCO, R. *see* MASSARELLA, J.

LIN, A. *see* MASSARELLA, J. W.

LIN,, E. T. *see* SAMBOL, N. C.

LINDBERG, C. *see* BORGSTROM L.

LINDE, M. & KIRCH, W. Non-invasive haemodynamic parameters in clinical pharmacology. What can the Heather-index be used for? 688P

LINDPAINTER, K., JIN, M., WILHELM, M., TOTH, M. & GANTEN, D. Aspects of molecular biology and biochemistry of the cardiac renin-angiotensin system, 159S

LINDSTROM, B. *see* MORTIMER, O.

LINDUP, W. E. *see* BARKER, C. E.

LIPWORTH, B. J., MCDEVITT, D. G. & STRUTHERS, A. D. ECG and systemic responses to inhaled salbutamol are due to pulmonary rather than gut absorption, 662P

LIPWORTH, B. J., MCDEVITT, D. G. & STRUTHERS, A. D. Systemic β-adrenoceptor responses to salbutamol given by metered-dose inhaler alone with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects, 691

LIPWORTH, B. J., MCFARLANE, L. C., COUTIE, W. & MCDEVITT, D. G. A dose-ranging study to evaluate the cardiosensitivity of atenolol in normal subjects, 684P

LITWAK, M. S. *see* AREZZO, J. C.

LITTLE, C. *see* SAGER, G.

LITTLETON, P. *see* HOSKIN, P. J.

LIVINGSTON, J. H., BEAUMONT, D., ARZIMANOGLOU, A. & AICARDI, J. Vigabatrin in the treatment of epilepsy in children, 109S

LOCKEY, D. & BATEMAN, D. N. Effect of oral activated charcoal on quinine elimination, 92

LOFGREN, A. *see* HASSELSTROM, J.

LOQUET, PH., BROUGHTON PIPKIN, F., SYMONDS, E. M. & RUBIN, P. C. Blood velocity waveform changes in umbilical and arcuate arteries during angiotensin II infusion in human subjects, 109P

LOUARN, F. *see* BELEC, L.
LUCKE, G. *see* BAUMGARTNER, H.

MABADEJE, A. F. B. *see* BOOBIS, A. R.
MACDONALD, F. C., GOUGH, K. J., NICOLL, R. A. G. & DOW, R. J. Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac, 453
MACDONALD, F. C. *see* MACCLEAN, D.
MACDONALD, I. A. *see* KERR, D.
MACDONALD, N. J., ELLIOTT, H. L., HOWIE, C. A. & REID, J. L. Age and the pharmacodynamics and pharmacokinetics of benazepril, 707P
MACDONALD, T. M. *see* FREESTONE, S.
MACDONALD,, T. M., JEFFREY, R. F. & LEE, M. R. The renal and haemodynamic effects of a 10 h infusion of glutamyl-L-dopa in normal men, 682
MACDONALD, T. M., JEFFREY, R. F., MUIR, A. L. & LEE, M. R. A preliminary study of fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease, 662
MACFAYDEN, R. J., LEES, K. R., DEVISSAGUET, J. P. & REID, J. L. Pharmacokinetic analysis of perindoprilat infusions in normal subjects, 678P
MACHEKA, B. M. *see* STEIN, C. M.
MACKLIN, B. S. *see* ROBERTSON, D. R. C.
MACCLEAN, D., MITCHELL, E. T., LAING, E. M. T., MACDONALD, F. C., GOUGH, K. J., DOW, R. J. & MCDEVITT, D. G. Comparison of the efficacy and acceptability of nicardipine and propranolol, alone and in combination, in mild to moderate hypertension, 571
MACPHEE, G. J. A. *see* LARKIN, J. G.
MADDEN, S., BACK, D. J., MARTIN, C. A. & ORME, M. L'E. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa, 295
MAKEDOU, A., HEDGES, A. & TURNER, P. The effect of propranolol on buccal potential difference, 676P
MAKEDOU, A., JACKSON, S. H. D., JAMIESON, M. J. & LI KAM WA, T. C. Dose-response curves – a teaching exercise, 114P
MALLET, A. I., NORRIS, P., RENDELL, N. B., WONG, E. & GREAVES, M. W. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and *N*-methylimidazole acetic acid in urine of patients with mastocytosis, 88
MANARA, A. R. *see* PARK, G. R.
MANFRED, R. *see* FILLASTRE, J. P.
MANNI, R. *see* COSI, V.
MANSOR, S. M., NAVARATNAM, V., MOHAMED, M., HUSSEIN, S., KUMAR, A., JAMALUDIN, A. & WERNSDORFER, W. H. Single dose study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers, 381
MAPPES, A. *see* MERKI, H. S.
MARKS, V. *see* SCOTT, N. R.
MARQUIS, P. *see* LIEGEOIS-CHAUVEL, C.
MARTIN, C. A. *see* MADDEN, S.
MASSARELLA, J., DEFEO, T., LIN, A., LIMJUCO, R. & BROWN, A. The pharmacokinetics and dose proportionality of cilazapril, 199S
MASSARELLA, J. W., DEFEO, T., BROWN, A. N., LIN, A. & WILLS, R. J. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril, 205S
MATHIAS, C. J. *see* RAIMBACH, S. J.
MATILAINEN, R., PITKANEN, A., RUUTIAINEN, T., MERVAALA, E. & REIKKINEN, P. Vigabatrin in epilepsy in mentally retarded patients, 113S
MATTIE, H. *see* BINS, J. W.
MATTILA, M. E. & MATTILA, M. J. Comparison of tablet and controlled release capsule of diazepam: plasma levels and effects on performance, 692P
MATTILA, M. J. *see* MATTILA, M. E.
MATTSON, R. H. *see* BROWNE, T. R.
MAWER, G. E. *see* JOYCE, P. W.
MCALPINE, L. G. & THOMSON, N. C. The effect of indomethacin and enalapril on the cutaneous response to bradykinin, 700
MCBURNEY, A. *see* AYESH, R.
MCCLELLAND, G. R. *see* WESNES, K. A.
MCCOLL, K. E. L. *see* HERRICK, A. L.
MCDEVITT, D. G. *see* CURRIE, D.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* LEWIS, R.
MCDEVITT, D. G. *see* MACLEAN, D.
MCDEVITT, D. G. *see* MCLAY, J.
MCEWAN, J. R. *see* CHOUDRY, N.
MCEWEN, J. *see* WILLIAMS, P. E. O.
MCFARLANE, L. C. *see* LIPWORTH, B. J.
MCGILLOWAY, S. *see* COOPER, S. J.
MCKAIGUE, J. P. *see* HARRON, D. W. G.
MCKAIGUE, J. P., HARRON, D. W. G., RIDDELL, J. G. & SHANKS, R. G. Effects of UK-52,046, an α_1-adrenoceptor antagonist, on baroreflex sensitivity in man, 679
MCLAY, J. *see* CHOPRA, M.
MCLAY, J. *see* CURRIE, D.
MCCLAY, J. *see* LEWIS, R., STRUTHERS, A. & MCDEVITT, D. G. The effects of chronic digoxin therapy upon neuroendocrine function in patients with atrial fibrillation, 117P
MCLELLAN, A. *see* LARKIN, J. G.
MCLAY, J., MCMURRAY, J. & STRUTHERS, A. D. Captopril causes a fall in ANF and an anti-natriuresis in chronic heart failure, 655P
MCMAHON, M. *see* HARRON, D. W. G.
MCMURRAY, J. *see* CHOPRA, M.
MCMURRAY, J. *see* MCLAY, J.
MCMURRAY, J. J. *see* SEIDELIN, P. H.
MCMURRAY, J. J., SEIDELIN, P. H., BROWN, R. A. & STRUTHERS, A. D. Noradrenaline attenuates the natiuretic effect of atrial natriuetic factor in man, 7
MCNAMARA, P. *see* COLANGELO, P.
MCVEIGH, G. E., DULIE, E. B, RAVENSCROFT, A., GALLOWAY, D. B. & JOHNSTON, G. D. Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension, 523.
MEINEKE, I. *see* DE MEY, C.
MELDRUM, B. S. GABAergic mechanisms in the pathogenesis and treatment of epilepsy, 3S
MENARD, J. *see* DE GASPARO, M.
MEREDITH, P. A., ELLIOTT, H. L., REID, J. L. & FRANCIS, R. J. The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension, 263S
MEREDITH, P. A. *see* HARRIGAN, J. R.
MEREDITH, P. A. *see* MILLER, S. H. K.

MERKI, J. S., KEMPF, M., MAPPES, A., HEIM, J., ROEHMEL, J. & WALT, R. P. Effect of Wy-45,727 on 24h intragastric acidity in twenty normal volunteers, 135
MERVAALA, E., *see* MATILAINEN, R.
MESKENS, C. *see* CALES, P.
MEYER, PH. *see* FRISK-HOLMBERG, M.
MICHEL, M. C. *see* BRODDE, O. E.
MICHELUCCI, R. & TASSINARI, C. A. Response to vigabatrin in relation to seizure type, 119S
MIKETTA, R. M. *see* BROWNE, T. R.
MILLER, S. H. K., MEREDITH, P. A., SCHAFERS, R. F. & ELLIOTT, H. L. A preliminary pharmacokinetic and pharmacokinetic and pharmacodynamic evaluation of a novel α_1-adrenoceptor antagonist UK 52046, 683P
MILLIGAN, K. R. *see* DUNDEE, J. W.
MILLS, K. B. *see* JOYCE, P. W.
MILTON, K. A., EDWARDS, G., WARD, S. A., L'E ORME, M. & BRECKENRIDGE, A. M. The effect of food on the pharmacokinetics of halofantrine in man after the administration of a single oral dose, 671P
MINAMISAWA, K. *see* SHIONOIRI, H.
MISTRY, R. *see* FURNISS, J.
MITCHELL, D. M. *see* AL-MUSTAFA, Z. H.
MITCHELL, E. T. *see* MACLEAN, D.
MITCHELL, J. R. A. *see* MURPHY, J. J.
MITCHELL, S. C. *see* AYESH, R.
MOELKER, H. C. T. *see* STIEKEMA, J. C. J.
MOHAMED, M. *see* MANSOR, S. M.
MONTASTRUC, J. L. *see* VALET, P.
MONTASTRUC, P. *see* VALET, P.
MOORE, M. R. *see* HERRICK, A. L.
MOOSER, V. *see* BURNIER, M.
MORGAN, M. Y. *see* SCOTT, N. R.
MORGAN, R. *see* FORSYTH, D. R.
MORTIMER, O., LINDSTROM, B., LAURELL, H. BERGMAN, U. & RANE, A. Dextromethorphan: polymorphic serum pattern of the *O*-demethylated and didemethylated metabolites in man, 223
MOULIN, B. *see* FILLASTRE, J. P.
MOULIN, M. *see* GRAM, L. F.
MOULDS, R. F. W. *see* JOHNSON, G. J.
MOWAT, A. P. *see* GORCHEN, A.
MULCAHY, F. *see* BARRY, M.
MULLEY, B. A. *see* CHRYSTYN, H.
MUMFORD, J. P. *see* BEN-MENACHEM, E.
MUMFORD, J. *see* COSI, V.
MUMFORD, J. P. & DAM, M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy, 101S
MUNDAY, A. *see* LARKIN, J. G.
MURPHY, J. J., HEPTINSTALL, S. & MITCHELL, J. R. A. A controlled trial of feverfew in the prophylaxis of migraine, 108P
MURRAY, S. *see* BOOBIS, A. R.

NALINE, E. *see* BRION, N.
NAVARATHAM, V. *see* MANSOR, S. M.
NEILL,, P. *see* STEIN, C. M.
NICHOLLS, A. J., PARKER, J. E. & POSNER, J. Effect of enalapril and atenolol alone or in combination on blood pressure in healthy volunteers, 659P
NICHOLSON, A. N. & PASCOE, PETA A. Dopaminergic transmission and sleep in man: studies with pemoline and pimozide, 110P
NICHOLSON, A. N., PASCOE, PETA A. & BELYAVIN, A. J. Modulation of rapid eye movement sleep and sleep continuity in man by drugs which modify monoaminergic transmission, 695P
NICHOLSON, E. *see* ISAH, A. O.
NICHOLSON, K. G. *see* JONKMAN, J. H. G.
NICHOLSON, P. W. WALKER, C. A., DICKINS, J., O'NEILL, C. J. A., BOWES, S. G., DESMUKH, A. A., DOBBS, S. M. & DOBBS, R. J. Use of delayed auditory feedback to assess cognitive function in Parkinson's disease, 697P
NICOLL, R. A. G. *see* MACDONALD, F. C.
NILSEN, O. G., SELLEVOLD, O. F. M., ROMFO, O. S., SMEDSRUD, A., GRYNNE, B., WILLIAMS, P. E. O. & KLEINBLOESEM, C. H. Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients, 323S
NILSSON, M. *see* PERSSON, L. I.
NOLAN, L., KENNY, R. & O'MALLEY, K. The need for reassessment of digoxin prescribing for the elderly, 367
NORMAN, A. J. *see* HAWKEY, C. J.
NORRIS, P. *see* MALLET, A. I.
NUSSENBERGER, J. *see* BURNIER, M.
NUSSENBERGER, J. *see* DE GASPARO, M.
NUSSENBERGER, J. *see* WAEBER, B.
NYAZEMA, N. S. *see* STEIN, C. M.
NYBERG, L. *see* BORGSTROM, L.

OLIVER, K. S., DENNIS, M. J. & LEARY, W. P. P. The pharmacokinetics of acebutolol in African Negro and White Caucasian volunteers, 670P
OLMER, M. *see* VERNILLET, L.
O'MALLEY, K. *see* NOLAN, L.
O'NEILL, C. J. A. *see* BOWES, S. G.
O'NEILL, C. J. A. *see* NICHOLSON, P. W.
OOSTERHIUS, B. *see* JONKMAN, J. H. G.
ORME, M. L'E .*see* BALL, S. E.
ORME, M., HARRY, J., ROUTLEDGE, P. & HOBSON, S. Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field, 125
ORME, M. L'E. *see* IRVIN, L. E.
ORME, M. L'E. *see* MADDEN, S.
ORME, M. L'E. *see* MILTON, K. A.
ORME, M. L'E. *see* WINSTANLEY, P. A.
ORR, J. M. *see* PANESAR, S. K.
OTTOSSON, A., JANSEN, I. & EDVINSSON, L. Pharmacological characterization of histamine receptors in the human temporal artery, 139
OYEWO, E. A. *see* AJAYI, A. A.

PANESAR, S. K., ORR, J. M., FARRELL, K., BURTON, R. W., KASSAHUN, K. & ABBOTT, F. S. The effect of carbamazepine on valproic acid disposition in adult volunteers, 323
PANTIERI, R. *see* LIEGOIS-CHAUVEL, C.
PARK, B. K. *see* RILEY, R. J.
PARK, G. R., MANARA,, A. R. & DAWLING, S. Extrahepatic metabolism of midazolam, 636
PARK, G. R. *see* SHELLEY, MARIE P.
PARKER, J. E. *see* NICHOLLS, A. J.

PARR, G., DAREKAR, B., FLETCHER, A. & BULPITT, C. J. Joint pain and quality of life: results of a randomised trial, 235
PASCAL, J. P. *see* CALES, P.
PASCOE, P. A. *see* NICHOLSON, A. N.
PASSMORE, A. P., COPELAND, S. & JOHNSTON, G. D. A comparison of the effects of ibuprofen and indomethacin upon renal haemodynamics and electrolyte excretion in the presence and absence of frusemide, 483
PASSMORE, A. P. *see* JOHNSTON, G. D.
PASSMORE, A. P., WHITEHEAD, E. M. & JOHNSTON, G. D. Comparison of the acute renal and peripheral vascular responses to frusemide and bumetanide at low and high dose, 305
PATERSON, J. R. *see* FERNER, R. E.
PAULSON, J. *see* BORGSTROM, L.
PAVLOU, H. *see* FUNCK-BRETANO, C.
PAYS, M. *see* BRION, N.
PEAKE, M. D. *see* CHRYSTYN, H.
PEAKER, S. *see* KUMAR, S.
PENRY, J. K. *see* BROWNE, T. R.
PERSSON, L. I. *see* BEN-MENACHEM, E.
PERSSON, L. I., RONNBACK, L., BEN-MENACHEM, E., ERIKSSON, P. & NILSSON, M. Changes in CSF and brain soluble proteins following vigabatrin treatment in rats, 73S
PERUCCA, E. *see* COSI, V.
PESSAYRE, D. *see* GHERARDI, R.
PETRIE, J. C. *see* COUNDOURIS, J. A.
PETRIE, J. C. *see* SCOTT, A. K.
PETRIE, J. C. *see* WEBSTER, J.
PINTA, P. *see* FILLASTRE, J. P.
PITKANEN, A. *see* MATILAINEN, R.
PITKANEN, A. *see* REIKKINEN, P. J.
PIXLEY, F. J. *see* WARREN, J. B.
POSNER, J. *see* NICHOLLS, A. J.
POSNER, J. *see* ROLAN, P.
PRESCOTT, L. F., HAMILTON, A. R. & HEYWORTH, R. Treatment of quinine overdosage with repeated oral charcoal, 95
PRESTON, SALLY, J., ARNOLD, M. H., BELLER, ELAINE M., BROOKS, P. M. & WATSON BUCHANAN, W. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis, 609
PRICE, D. *see* FEELY, M.
PRICHARD, B. N. C. *see* TOMLINSON, B.
PROVENCHER, P. *see* LACOURCIERE, Y.
PULLAR, T. *see* KUMAR, S.
PYYKO, K. *see* KOULU, M.

RAIMBACH, S. J., CORTELLI, P., KOONER, J. S., BANNISTER, R. & MATHIAS, C. J. Cardiovascular effects of SMS 201-995 (octerotide) in chronic human autonomic failure, 101P
RAFTERY, E. B. *see* HEBER, M. E.
RAJAGURU, S. *see* FRANCIS, R. J.
RAJAGURU, S. *see* WILLIAMS, P. E. O.
RAMSAY, L. E. *see* LENNARD, M. S.
RANE, A. *see* MORTIMER, O.
RAVAUD, A. *see* CALES, P.
RAVENSCROFT, A. *see* MCVEIGH, G. E.
RAWLES, J. *see* WEBSTER, J.
RAWLINS, M. D. *see* AL-MUSTAFA, Z. H.
RAWLINS, M. D. *see* FERNER, R. E.
RAWLINS, M. D. *see* ISAH, A. O.
REGARDH, C. G. *see* EDGAR, B.
REID, J. L. *see* AHMED, J. H.
REID, J. L. *see* ELFELLAH, M. S.
REID, J. L. *see* ELLIOTT, H. L.
REID, J. L. *see* MACDONALD, N. J.
REID, J. L. *see* MACFAYDEN, R. J.
REID, J. L. *see* MEREDITH, P.A.
REID, J. L. *see* SCHAFERS, R. F.
REID, J. L. *see* WHYTE, K. F.
REIKKINEN, P. *see* MATILAINEN, R.
REIKKINEN, P. J., YLININ, A., HALONEN, T., SIVENIUS, J. & PITKANEN, A. Cerebrospinal fluid GABA and seizure control with vigabatrin, 87S
REMY, C. & BEAUMONT, D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy, 125S
RENONDIN, J-C., SUTTON, J. A. & FRASER, M. A single dose of theophylline prolongs intestinal transit but not gastric emptying, 702P
RENDELL, N. B. *see* MALLET, A. I.
RENONDIN, J-C. *see* TOMLINSON, B.
RENWICK, A. G. *see* ROBERTSON, D. R. C.
RENWICK, A. G. *see* RICHARDS, R.
REYNOLDS, D. J. *see* BROWN, M. J.
RICHARDS, R., FOWLER, CHRISTINE, SIMPSON, STEPHANIE F., RENWICK, A. G. & HOLGATE, S. T. Deep inspiration increases the absorption of inhaled sodium cromoglycate, 683
RICHARDSON, T. *see* JOYCE, P. W.
RICHENS, A. *see* BOLTON, J. B.
RICHENS, A. *see* RIMMER, E. M.
RIDDELL, J. G. *see* HARRON, D. W. G.
RIDDELL, J. G. *see* MCKAIGUE, J. P.
RIDDELL, J. G. *see* WHITEHEAD, E. M.
RIDLER, C. D. *see* KOVACS, I. B.
RILEY, R. J., LAMBERT, C., KITTERINGHAM, N. R. & PARK, B. K. A stereochemical investigation of the cytotoxicity of mianserin metabolites *in vitro*, 689
RIMMER, E. *see* BOLTON, J B.
RIMMER, E. M. & RICHENS, A. Interaction between viagbatrin and phenytoin, 27S
ROBERTS, C. J. C. *see* FORSYTH, D. R.
ROBERTSON, D. R. C., RENWICK, A. G., CROSS, N., MACKLIN, B. S., WALLER, D. G., WOOD, N. D. & GEORGE, C. F. The influence of levodopa on gastric emptying in man, 700P
ROBERTSON, D. R. C., WOOD, N., EVEREST, H., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. The effect of carbidopa on age related changes in the pharmacokinetics of levodopa, 106P
ROBINET, D. *see* FLOUVAT, B.
RODEN, D. M. *see* FUNCK-BRENTANO, C.
ROEHMEL, J. *see* MERKI, H. S.
ROGERS, H. J. AL-HABET, S. M. H.
ROLAN, P., ADAMS, J. & POSNER, J. A model for examining the onset of H_1-receptor antagonism in man, 694P
ROMFO, O. S. *see* NILSEN, O. G.
RONNBACK, L. *see* PERSSON, I.
ROSSI, A. *see* FLOUVAT, B.
ROUTLEDGE, P. *see* ORME, M.
ROUTLEDGE, P. A. *see* WATT, A. H.
ROWLAND, M. *see* GILL, T. S.

ROWLAND, M. *see* GUPTA, S. K.
ROY-CHAUDHURY, P. *see* SCOTT, A. K.
RUBIN, P. C. *see* HORN, E. H.
RUBIN, P. C. *see* LOQUET, PH.
RUDDOCK, C. J. S. *see* STOTT, J. R. R.
RUSSEL, F. G. M. *see* DE MEIJER, P. H. E. M.
RUUTIAINEN, T. *see* MATILAINEN, R.

SAGER, G., JAEGER, R. & LITTLE, C. Binding of prazosin and propranolol at variable α$_1$-acid glycoprotein and albumin concentrations, 229
SAINSBURY, R. *see* BEGG, E. J.
SALEH, S., JOHNSTON, A. & TURNER, P. The serum protein binding of medifoxamine, 708P
SAMBOL, N. C., UPTON, R. A., CHREMOS, A. N., LIN, E. T. & WILLIAMS, R. L. A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow, 83
SANDLER, D. A., GARNER, S. T. & FELLOWS, A. 'I've no idea what they sent me out on, Doctor!' Would an information booklet at discharge help? 699P
SANDLER, D. A. *see* HEPTINSTALL, S.
SANTONI, J. PH. *see* BACKHOUSE, C. I.
SARMINI, H. *see* FLOUVAT, B.
SAUNDERS, J. E. *see* WARD, S. A.
SAWE, J. *see* HASSELSTROM, J.
SAZDOVITCH, V. *see* HAUW, J. J.
SCHAFERS, R. F., ELLIOTT, H. L., HOWIE, C. A. & REID, J. L. Preliminary clinical pharmacological studies with the novel α$_1$-adrenoceptor antagonist UK 52-046, 102P
SCHAFERS, R. F. *see* MILLER, S. H. K.
SCHAPIRA, M. *see* WAEBER, B.
SCHECHTER, P. J. Clinical pharmacology of vigabatrin, 19S
SCHECHTER, P. J. *see* BEN-MENACHEM, E.
SCHEININ, M. *see* KOULU, M.
SCHOUSBOE, A. *see* GRAM, L.
SCHROEDER, C. E. *see* AREZZO, J. C.
SCOTT, A. K., ROY-CHAUDHURY, P., WEBSTER, J. & PETRIE, J. C. Does a selective 5-hydroxytryptamine antagonist (ICI 169, 369) lower blood pressure in hypertensive patients? 417
SCOTT, B. R. *see* JAMES, J. E.
SCOTT, M. *see* HARRON, D. W. G.
SCOTT, N. *see* CHOPRA, M.
SCOTT, N. R., STAMBUK, D., CHAKRABORTY, J., MARKS, V. & MORGAN, M. Y. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease, 205
SEIDELIN, P. H. *see* MCMURRAY, J. J.
SEIDELIN, P. H. MCMURRAY, J. J., BROWN, R. A. & STRUTHERS, A. D. The effect of angiotensin II and noradrenaline alone and in combination on renal sodium excretion in man, 674
SELLEVOLD, O. F. M. *see* NILSEN, O. G.
SENARD, J. M. *see* VALET, P.
SERVICE, E. *see* LEWIS, R.
SEVER, P. S. *see* THOM, S.
SHANKS, R. G. *see* HARRON, D. W. G.
SHANKS, R. G. *see* HARRON, D. W. G.
SHANKS, R. G. *see* MCKAIGUE, J. P.
SHANKS, R. G. *see* WHITEHEAD, E. M.
SHARMAN, J. R. *see* BEGG, E. J.
SHARPLEY, A. L. *see* SOLOMON, R. A.
SHAWKET, S. A., DICKERSON, C., HAZELMAN, B. & BROWN, M. J. Comparative study with CGRP in Raynaud's phenomenon and normal volunteers, 689P
SHAWKET, S. A., HAZELMAN, B. & BROWN, M. J. Comparison of vasodilating actions of calcitonin gene related peptide, ATP and PGI_2 in Raynaud's phenomenon, 119P
SHELLEY, MARIE P., DIXON, J. S. & PARK, G. R. The pharmacokinetics of midazolam following orthotopic liver transplantation, 631
SHERRY, K. M. *see* BROWNE, T. R.
SHIONOIRI, H., GOTOH, E., SUGIMOTO, K. TAKASAKI, L., MINAMISAWA, K. & ISHII, M. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function, 283S
SILAS, J. H. *see* LENNARD, M. S.
SILKE, B., EVANS, J. M., VERMA, S. P., ZEZULKA, A. V. & TAYLOR, S. H. Pharmacodynamic study of nicardipine and atenolol using an echo Doppler cardiac output method, 685P
SIMOOYA, O. O. *see* WINSTANLEY, P. A.
SIMPSON, K. H., TRING, I. C. & ELLIS, F. R. An investigation of premedication with morphine given by the buccal or intramuscular route, 377
SIMPSON, P. M. *see* WESNES, K. A.
SIMPSON, STEPHANIE, F. *see* RICHARDS, R.
SIMPSON, P. M., WESNES, K. A. & CHRISTMAS, L. A computerised system for the assessment of drug-induced performance changes in young, elderly or demented populations, 711P
SINCLAIR, A. J. DAVIES, I. B. & WARRINGTON, S. J. Alfuzosin and the venous reflex response: studies in normal subjects, 19
SIOUFI, A. *see* LEFEBVRE, R. A.
SIVENIUS, J. *see* REIKKINEN, P. J.
SKRUMSAGER, B. K. *see* WARRINGTON, S. J.
SLUITER, H. E. *see* KLOKE, H. J.
SMART, W. M. *see* HALL, C. L.
SMEDSRUD, A. *see* NILSEN, O. G.
SMITH, D. B. *see* BROWNE, T. R.
SMITH, D. L. *see* CHAPMAN, K. R.
SMITH, J. C. *see* IRVIN, L. E.
SMITH, R. *see* BACON, P. J.
SMITH, R. L. *see* AYESH, R.
SMITH, S. E. *see* BACON, P. J.
SMITH, S. R. *see* LEWIS, HELEN M.
SMITH, W. E. *see* CHOPRA, M. L.
SOLOMON, R. A., FRISTON, K. J., SHARPLEY, A. L. & COWEN, P. J. The effect of lithium on slow wave sleep in man, 648P
SOONS, P. A., DE BOER, A. G., VAN BRUMMELEN, P. & BREIMER, D. D. Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study, 179
SPEIRS, C. J. *see* BOOBIS, A. R.
STANIFORTH, D. H. Oro-caecal transit time in man unaffected by 5-HT_3 antagonism: a comparison of BRL 24924 and BRL 43694, 701P
STAMBUK, D. *see* SCOTT, N. R.
STARK, R. D. *see* JESSUP, C. L.
STEIN, A. G., DANESHMEND, T. K., WARNOCK, D. W., BHASKAR, N., BURKE, J. & HAWKEY, C. J.

The effects of H_2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal, 105P

STEIN, C. M., THORNHILL, D. P., NEILL, P. & NYAZEMA, N. Z. Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol, 262

STEIN, C. M. GORA, N. P. & MACHEKA, B. M. Self-medication in urban and rural Zimbabwean communities, 697

STEWARD, D. L. *see* AREZZO, J. C.

STEWART-JONES, J. H. *see* DANIELS, S.

STEWART-JONES, J. H. *see* WRIGHT, S.

STIEGMAYER, A. *see* BAUMGARTNER, H.

STIEKEMA, J. C. J., WIJNAND, H. P., VAN DINTHER, TH. G., MOELKER, H. C. T., DAWES, J., VINCHENZO, A. & TOEBERICH, H. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers, 39

STOTT, J. R. R., BARNES, G. R., WRIGHT, R. J. & RUDDOCK, C. J. S. The effect of motion sickness and oculomotor function of GR 38032F, a 5-HT_3-receptor antagonist with anti-emetic properties, 147

STROEMER, K. *see* KIRCH, W.

STRUTHERS, A. D. *see* LIPWORTH, B. J.

STRUTHERS, A. D. *see* MCLAY, J.

STRUTHERS, A. D. *see* MCMURRAY, J. J.

STRUTHERS, A. D. *see* SEIDELIN, P. H.

STUCK, A. E., BRINDLEY, C. J. BUSSLINGER, A. & FREY, F. J. Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis, 301

SUGIMOTO, K. *see* SHIONOIRI, H.

SUN, P. *see* HAUW, J. J.

SURTEES, M., FACCHINI, V., YEANG, CLOW, K. W. & DENNIS, M. J. Radioimmunoassay of a novel anti-allergic compound (RP 42068) and its application to the analysis of RP 42068 in plasma, 111P

SUTHERLAND, M. *see* LARKIN, J. G.

SUTTON, J. A. *see* RENONDIN, J-C.

SWALES, J. D. *see* HEAGERTY, A. M.

SWEENEY, KEVIN R., CHAPRON, DENNIS J., ANTAL, EDWARD J. & KRAMER, PAUL A. Differential effcts of flurbiprofen and aspirin on acetazolamide disposition in humans, 685

SWIFT, C. G. *see* WATT, A. H.

SYMONDS, E. M. *see* LOQUET, PH.

SZABADI, E. *see* BANJAR, W. M. A.

SZABADI, E. *see* THEOFILOPOULOS, N.

SZABO, G. K. *see* BROWNE, T. R.

TAKASAKI, L. *see* SHIONOIRI, H.

TARTARA, A. *see* COSI, V.

TASKER, T. C. G. *see* GILL, T. S.

TASSINARI, C. A. *see* MICHELUCCI, R.

TAYLOR, S. H. *see* SILKE, B.

TEDSTONE, J. E. *see* WILSON, J. F.

TEIRLYNCK, A. *see* LEFEBVRE, R. A.

TETT, S. E., CUTLER, D. J., DAY, R. O. & BROWN, K. F. Bioavailability of hydroxychloronquine tablets in healthy volunteers, 687

THEODOROU, A. E. *see* THILO, JULIA.

THEOFILOPOULOS, N., GRAY, C. M., SZABADI, E. & BRADSHAW, C. M. Comparison of the effects of fengabine and amitriptyline on psychomotor and autonomic functions in healthy volunteers, 691P

THILO, JULIA, LAWRENCE, K. M., THEODOROU, A. E., HORTON, R. W., BLACKWOOD, N., GREENWOOD, M., HOWICK, A., FINDLEY, L. & LEIGH, P. N. Platelet α_2-adrenoceptor binding differentiates benign essential tremor and Parkinson's disease, 650P

THOM, S., HUGHES, A. D., WOODALL, N. & SEVER, P. S. Endothelin causes prolonged vasoconstriction in the human forearm, 690P

THOMSON, A. H., KELLY, J. G. & WHITING, B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension, 57

THOMPSON, N. C. *see* MCALPINE, L. G.

THORNHILL, D. P. *see* STEIN, C. M.

TILL, A. E., DICKSTEIN, K., AARSLAND, T., GOMEZ, H. J., GREGG, H. & HICHENS, M. The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure, 199

TINDALL, H. *see* FEELY, M.

TINEL, M. *see* BELEC, L.

TJIA, J. F. *see* BACK, D. J.

TOEBERICH, H. *see* STIEKEMA, J. C. J.

TOMLINSON, B., RENONDIN, J-C., GRAHAM, B. R. & PRICHARD, B. N. C. α_1-adrenoceptor antagonism and haemodynamic effects of UK-52,046 compared with prazosin, 686P

TOTH, M. *see* LINDPAINTNER, K.

TRAN, M. A. *see* VALET, P.

TREGASKIS, B. *see* CURRIE, D.

TREGASKIS, B. *see* LEWIS, R.

TREIMAN, D. M. *see* BROWNE, T. R.

TRIGER, D. R. *see* BURNS, E.

TRING, I. C. *see* SIMPSON, K. H.

TRUMAN, C. A. *see* FORSYTH, D. R.

TSANACLIS, L. M. *see* WILSON, J. F.

TUCKER, G. T. *see* JACKSON, P. R.

TUCKER, G. T. *see* LENNARD, M. S.

TURNER, P. *see* AL-SEREITI, M. R.

TURNER, P. *see* DANIELS, S.

TURNER, P. *see* BLACKETT, A.

TURNER, P. *see* MAKEDOU, A.

TURNER, P. *see* SALEH, S.

TURNER, P. *see* WARRINGTON, S. J.

TURNER, P. *see* WRIGHT, S.

UPTON, R. A. *see* SAMBOL, N. C.

VALET, P., SENARD, J. M., DURRIEU, G., BERLAN, M., TRAN, M. A., MONTASTRUC, J. L. & MONTASTRUC, P. α-adrenoceptor supersensitivity in Parkinsonians with orthostatic hypotension, 682P

VALLANCE, P. *see* WEBB, D. J.

VAN BRUMMELEN, P. *see* DOORENBOS, C. J.

VAN BRUMMELEN, P. *see* SOONS, P. A.

VAN DINTHER, TH. G. *see* STIEKEMA, J. C. J.

VAN GINNEKEN, C. A. M. *see* DE MEIJER, P. H. E. M.

VAN HOOGDALEM, E. J., WACKWITZ, A. T. E., DE BOER, A. G., COHEN, A. F. & BREIMER, D. D. Rate-controlled rectal absorption enhancement of cefoxitin by co-administration of sodium salicylate or sodium octanoate in healthy volunteers, 75

VAN LIER, H. J. J. *see* DE MEIJER, P. H. E. M.

VAN STEVENINCK, A. L., COHEN, A. F. & WARD, T.

A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements, 712P

VAN TITS, L. J. H. GROSSE-WILDE, H., HAPPEL, M., KHALIFA, A. M. & BRODDE, O. E. β-adrenoceptor changes in leucocyte subpopulations after isoprenaline-infusion in healthy volunteers, 660P

VAN ZWIETEN, P. A. *see* BLAUW, G. J.

VERMA, S. P. *see* SILKE, B.

VERNILLET, L., BERTAULT-PERES, P., BERLAND, Y., BARRADAS, J., DURAND, A. & OLMER, M. Lack of effect of spiramycin on cyclosporin pharmacokinetics, 678

VINCHENZO, A. *see* STIEKEMA, J. C. J.

VINEL, J. P. *see* CALES, P.

VUORINEN, J. *see* KOULU, M.

WACKWITZ, A. T. E. *see* VAN HOOGDALEM, E. J.

WAEBER, B. *see* BURNIER, M.

WAEBER, B., JUILLERAT-JEANNERET, L., AUBERT, J. F., SCHAPIRA, M., NUSSENBERGER, J. & BRUNNER, H. R. Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors, 175S

WALKER, C. A. *see* NICHOLSON, P. W.

WALLER, D. G. *see* ROBERTSON, D. R. C.

WALT, R. P. *see* MERKI, H. S.

WALTER, G. E. *see* WHITEHEAD, E. M.

WALTERS, G. E. *see* WILLIAMS, P. E. O.

WARD, J. W. *see* AYESH, R.

WARD, S. A. *see* MILTON, K. A.

WARD, S. A., WATKINS, W. M., SAUNDERS, J. E., KOEH, D. K., GILLES, H. M., HOWELLS, R. E. & BRECKENRIDGE, A. M. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man, 698

WARD, T. *see* VAN STEVENINCK, A. L.

WARNOCK, D. W. *see* STEIN, A. G.

WARREN, J. B., PIXLEY, F. J. & DOLLERY, C. T. Importance of β_2-adrenoceptor stimulation in the suppression of intradermal antigen challenge by adrenaline, 173

WARRINGTON, S. J. *see* SINCLAIR, A. J.

WARRINGTON, S. J., TURNER, P. & SKRUMSAGER, B. K. Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine – a comparison with amitriptyline and placebo in healthy men, 343

WATERFALL, J. F. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor, 139S

WATERS, W. E. *see* GIBBS, SHARON.

WATKINS, W. M. *see* WARD, S. A.

WATT, A. H., BAYER, A., ROUTLEDGE, P. A. & SWIFT, C. G. Adenosine-induced respiratory and heart rate changes in young and elderly adults, 265

WATSON BUCHANAN, W. *see* PRESTON, SALLY J.

WEBB, D. J., BENJAMIN, N. & VALLANCE, P. The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs in healthy volunteers, 692

WEBSTER, J. *see* STOTT, A. K.

WEBSTER, J., WITTE, K., RAWLES, J., PETRIE, J. C. & JEFFERS, T. A. Evaluation of a long acting formulation of nicardipine in hypertension by clinic and home recorded blood pressures and Doppler aortovelography, 565

WELLSTEIN, A. *see* ESSIG, J.

WERNSDORFER, W. H. *see* MANSOR, S. M.

WESCHE, H. *see* DE MEY, C.

WESNES, K. A. *see* SIMPSON, P. M.

WESNES, K. A., SIMPSON, P. M., CHRISTMAS, L., MCCL, G. R. & JOINER, I. M. Acute cognitive effects of moclobemide and trazodone,alone and in combination with alcohol, in the elderly, 647P

WETZELS, J. F. M. *see* KLOKE, H. J.

WHITEHEAD, E. M. *see* PASSMORE, A. P.

WHITEHEAD, E. M., RIDDELL, J. G. & SHANKS, R. G. Effects of atenolol, nifedipine and their combination on the cardiovascular system and finger tremor in normal man, 683P

WHITEHEAD, E. M., WALTER, G. E., WILLIAMS, P. E. O. & JOHNSTON, G. D. Pharmacokinetics of intravenous cilazaprilat in normal volunteers, 711

WHITESMITH, R. *see* WHYTE, K. F.

WHITING, B. *see* THOMSON, A. H.

WHYTE, K. F., DE VANE, P. J., WHITESMITH, R., KELMAN, A. & REID, J. L. Effect of CGP 17/582, a selective β-adrenoceptor antagonist, on the haemodynamic and hypokalaemic response to adrenaline, 555

WIECK, A., HIRST, A. D., KUMAR, R., CHECKLEY, S. A. & CAMPBELL, I. C. Growth hormone secretion by human females in response to apomorphine challenge is markedly affected by menstrual cycle phase, 700P

WIJNAND, H. P. *see* STIEKEMA, J. C. J.

WILCOCK, G. K. *see* FORSYTH, D. R.

WILDER, B. J. *see* BROWNE, T. R.

WILHELM, M. *see* LINDPAINTNER, K.

WILKINSON, R. *see* FERNER, R. E.

WILLIAMS, C. *see* JESSUP, C. L.

WILLIAMS, FAITH M. *see* AL-MUSTAFA, Z. H.

WILLIAMS, F. M. *see* FERNER, R. E.

WILLIAMS, F. M. *see* ISAH, A. O.

WILLIAMS, J. *see* BOLTON, J. B.

WILLIAMS, J. *see* WILSON, J. F.

WILLIAMS, P. E. O. *see* FRANCIS, R. J.

WILLIAMS, P. E. O., BROWN, A. N., RAJAGURU, S., FRANCIS, R. J., WALTERS, G. E., MCEWEN, J. & DURNIN, C. The pharmacokinetics and bioavailability of cilazapril in normal man, 181S

WILLIAMS, P. E. O., BROWN, A. N., RAJAGURU, S., WALTERS, G. E., MCEWEN, J. & DURNIN, C. A pharmacokinetic study of cilazapril in elderly and young volunteers, 211S

WILLIAMS, P. E. O. *see* FRANCIS, R. J.

WILLIAMS, P. E. O. *see* NILSEN, O. G.

WILLIAMS, P. E. O. *see* WHITEHEAD, E. M.

WILLIAMS, R. L. *see* SAMBOL, N. C.

WILLS, R. J. *see* MASSARELLA, J. W.

WILSON, D. *see* FERNER, R. E.

WILSON, J. F., TSANACLIS, L. M., WILLIAMS, J., TEDSTONE, J. E. & RICHENS, A. An interlaboratory comparison of techniques for the measurement of digoxin in serum, 672P

WINSTANLEY, P. A. *see* IRVIN, L. E.

WINSTANLEY, P. A., SIMOOYA, O. O., EDWARDS, G., L'E ORME, M., KOFI EKUE, J. M. & BRECKEN-

RIDGE, A. M. The disposition of amodiaquine in Zambians with malaria, 644P
WIRTH, C. *see* BRODDE, O. E.
WITTE, K. *see* WEBSTER, J.
WOLF, C. R. *see* BALL, S. E.
WONG, E. *see* MALLET, A. I.
WOOD, A. J., ARONSON, J. K., BUNCH, C. & GRAHAME-SMITH, D. G. A study of the transport of lithium across the erythrocyte membrane *in vivo* and of the effects of the ion transport inhibitors digoxin and dipyridamole, 686
WOOD, J. M. *see* DE GASPARO, M.
WOOD, N. *see* ROBERTSON, D. R. C.
WOODALL, N. *see* THOM, S.
WOODS, H. F. *see* LENNARD, M. S.
WOOSLEY, R. L. *see* FUNCK-BRENTANO, C.
WRIGHT, R. J. *see* STOTT, J. R. R.
WRIGHT, S., EDGAR, D. F., STEWART-JONES, J. H. & TURNER, P. Comparison of topical betaxolol, carteolol, metipranolol and saline on intraocular pressure in normal volunteers, 696P
WYNN, V. *see* DEVENPORT, M. H.

YEANG, Y. *see* SURTEES, M.
YLINEN, A. *see* REIKKINEN, P. J.

ZARIFIAN, E. *see* GRAM, L. F.
ZERKOWSKI, H. R. *see* BRODDE, O. E.
ZEZULKA, A. V. *see* SILKE, B.
ZIMMER, R. H. *see* KOULU, M.
ZMIROU, D. *see* FERLEY, J. P.

SUBJECT INDEX

(P = proceedings; S = supplement)

Absolute bioavailability, 181S
Absorption, 75, 179
ACE, 211S
Acebutolol, 670P
ACE inhibition, 57, 175S, 189S, 199S, 205, 225S, 303S, 323S
ACE inhibitors, 217S
Acetazolamide, 599, 866
α_1-acid glycoprotein, 229, 257, 665P
Acitretin, 301
Activated charcoal, 92, 703P
Active metabolite, 515
Active renin, 589
Acute phase response, 257
Adenosine, 165, 265
Adrenaline, 100P, 173, 555
α_1-adrenoceptors, 276
α_1-adrenoceptor antagonist, 102P, 680P, 683P, 686P
α_1-adrenoceptor supersensitivity, 682P
α_2-adrenoceptors, 687P
α_2-adrenoceptor antagonist, 649P, 679P
α_2-adrenoceptor binding, 650P
Adult volunteers, 323
Adverse drug reactions, 711P
Africans, 400
Age, 106P, 265, 707P, 711P
AIDS, 667P
Albumin, 229
Alcohol, 647P, 693P
Alfuzosin, 19
Alinidine, 23
Allergen bronchial challenge, 628
Allergy, 111P
Almitrine, 387
Ambulatory recording, 359
Ambulatory pressures, 371
Amitriptyline, 691P
Amlodipine, 359
Amodiaquine, 644P
Analgesics, 235, 377
Analysis of corticosteroids, 285
Angina, 23
Angiotensin, 167S
Angiotensin I, 133S, 217S
Angiotensin II, 109P, 589, 805
Angiotensin converting enzyme, 139S, 159S, 167S, 267S, 289S
Angiotensin converting enzyme activity, 297S
Angiotensin converting enzyme inhibitor, 133S, 151S, 243S, 263S, 275S, 283S, 337, 396, 656P, 707P
Animal toxicology, 69S
Antacids, 677P
Anticholinergic effect, 343
Anti-coagulant, 469
Anticonvulsant, 491
Anti-emetic, 147
Antiepileptic drugs, 668P
Antifungal, 851
Antigen, 173
Antihistamines, 116P
Antinatriuretic factor, 655P
Antiviral drug, 111P
Anxiety states, 651P
Apomorphine, 700P
Arcuate artery, 109P
Asparagus, 641, 642
Aspirin, 104P, 121P, 609, 866
Asthma, 268, 831
Atenolol, 23, 112P, 115P, 268, 659P, 683P, 684P, 885P
ATP, 119P
Atrial fibrillation, 103P, 117P, 652P
Atrial natriuretic factor, 7
Atrial natriuretic peptide, 13, 243S
Autonomic failure, 101P
Autonomic function, 303S, 400
Azidothymidine, 667P

β-adrenoceptor, 31, 529, 660P, 837
β_1-adrenoceptor, 661P
β-adrenoceptor antagonists, 114P
β-adrenoceptor blockade, 555
β-adrenoceptor blockers, 405
β_2-adrenoceptor antagonist, 173
Baroreflex, 303S
Baroreflex sensitivity, 679P
Bayesian analysis, 21S
Benazepril, 707P
Benzylpenicillin, 291
Betaxolol, 696P
Bioavailability, 39, 313, 499, 583, 677P, 771
Blindness, 95
Blood pressure, 139, 275S, 297S, 303S, 711
Bradykinin, 175S, 337, 831, 870
Brain soluble, 73S
BRL 24924, 701P
BRL 39123, 111P
BRL 43694, 701P
Bromocriptine, 159
Bronchogenic carcinoma, 646P
Buccal, 499
Buccal absorption, 123P
Buccal potential difference, 676P
Bumetanide, 305
Buprenorphine, 453

Caffeine, 205, 507
Calcitonin gene related peptide, 119P, 689P
Calcium, 118P
Calcium antagonists, 411
Calcium channel antagonists, 696P, 706P
Captopril, 159S, 175S, 396, 655P

Carbamazepine, 313, 323
Carbidopa, 106P
3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid, 675P
Carcinogenic heterocyclic amine, 709P
Cardiac, 268
Cardiac glycosides, 103P
Cardiac renin-angiotensin system, 159S
Cardiovascular reflexes, 139S
Carteolol, 696P
Cefotoxin, 75
Children, 109S
Chloramphenicol, 262
Chloroquine, 116P
Cholinesterase inhibitor, 674P
Chronic heart failure, 655P
Cilazapril, 133S, 139S, 151S, 167S, 189S, 199S, 211S, 235S, 249S, 263S, 267S, 275S, 283S, 289S, 297S, 303S, 309S, 317S, 323S
Cilazaprilat, 159S, 181S, 211S, 243S, 267S, 874
Cimetidine, 83, 469, 677P
Cirrhosis, 665P, 763
Cirrhotic patients, 205
13-Cis acitretin, 301
Clearance, 353
Clemastine, 116P
Clinical trials, 125, 329, 609
Clomiphene, 639
Clonidine, 687P
Combination therapy, 571
Compensation, 715
Complex partial seizures, 95S, 119S
Compliance, 101P
Congestive heart failure, 199
Concentration-time data, 664P
Concentration ratios, 676P
Consent, 715
Controlled release, 313, 499
Converting enzyme, 199
Copal UA-251, 565
Cortisol, 243
Corticosteroids, 285
Creatinine clearance, 275S
Cromakalim, 112P
Cromoglycate, 861
Cryopreservation, 666P
CSF, 19S
Cycloguanil, 781
Cyclopenthiazide, 523
Cyclosporin, 353, 475, 706P, 789
Cystic fibrosis, 291
Cytotoxicity, 825

Debrisoquine, 223, 387, 423, 429, 435, 646P
Deep inspiration, 861
Delayed auditory feedback, 697P
Dementia, 674P, 711P
Desogestrel, 295
Dextromethorphan, 223, 387
Diabetes, 101P
Diazepam, 692P
Diclofenac, 453
Digoxin, 103P, 117P, 367, 652P, 672P, 749
Diltiazem, 268, 652P, 706P
Dipyramidole, 749
Disappearance curves, 461
Disposition, 866
Diuretic, 525
Dopaminergic agonist, 159
Dopaminergic transmission, 110P
Doppler aortovelography, 565
Dose-response curves, 114P
Drug absorption, 23S
Drug information, 653P
Drug interaction, 262, 272, 391, 435
Drug metabolism, 795
Drug oxidation, 622
Drug utilization, 367, 741
Duration dependency, 353

Echo Doppler cardiac output, 685P
Effective renal plasma flow, 235S
Efficacy, 101S, 125S,
Elderly, 39, 211S, 279, 367, 445, 519, 647P, 653P
Electrocardiograph, 837
Enalapril, 115P, 191, 400, 659P, 870
Endothelin, 690P
Enhanced elimination, 95
Enzyme induction, 313
Epilepsy, 3S, 61S, 87S, 95S, 113S, 843
Erythrocyte, 749
Erythromycin, 475
Essential hypertension, 303S, 371
Ethanol, 103
Ethics, 715
Ethinyloestradiol, 644P
Ethnic differences, 670P
Ethno-racial difference, 121P
Evoked potentials, 53S, 61S
Exercise, 549, 653P, 704P
Exercise tolerance, 400
Extra-hepatic, 636
Eyedrops, 1
Eye movements, 147

Family study, 622
Famotidine, 83
Felodipine, 67
Femoxetine, 343
Fengabine, 691P
Fenoldopam, 662P
Fenoterol, 268
Feverfew, 108P
Fibrinogen receptor, 681P
Flosequinan, 549
Fluconazole, 851
Flurbiprofen, 866
Food, 23S, 671P, 704P
Free radical, 396
Frusemide, 235S, 305, 483

GABA, 3S, 19S, 47S, 53S, 87S, 113S
GABA-derivatives, 113S
GABA release, 13S
GABA-T, 35S
GABA-transaminase, 13S
γ-vinyl GABA, 13S, 47S
Gastric emptying, 700P, 702P

Gastric mucosa, 704P
General practice, 235
Generalised seizures, 119S
Genetic polymorphism, 272, 429, 622, 646P
Glaucoma, 599
Glomerular filtration, 235S
Gludopa, 811
Glyceryl trinitrate, 23, 610, 619
Glycosaminoglycuronans, 39
GR 38032F, 147
Growth hormone, 700P
Gut wall metabolism, 295

Haemodialysis, 301
Haemodynamics, 139S, 267S, 268
Haemodynamic effects, 189S, 303S
Halofantrine, 671P
Haloperidol, 272
Health status, 235
Heart failure, 167S, 400, 529
Heart rate, 265, 303S
Heather index, 688P
Heparinoid, 39
Hepatic blood flow, 83
Hepatocytes, 666P
Hepatotoxicity, 120P
Histamine, 88
Histamine receptors, 139
Histamine H_2-receptor agonist, 83
Histamine H_1-receptor antagonism, 694P
Home-recordings, 565
Homeopathy, 329
Hormonal effects, 189S
H.p.l.c. 111P, 789
H_2-receptors, 139
H_2-receptor antagonists, 105P, 135
5-HT antagonists, 417
5-HT_2 receptor antagonist, 122P
5-HT_3 receptor antagonist, 663P, 701P
5-HT-uptake inhibition, 543
5-hydroxytryptamine, 417
5-hydroxytryptamine antagonist, 147
Human, 49
Human albumin, 675P
Human temporal arteries, 139
Hydrochlorothiazide, 323S, 371, 658P
Hydroxychloroquine, 771
Hyoscine, 147
Hypertension, 57, 115S, 283S, 289S, 317S, 337, 359, 411, 417, 523, 565, 571, 658P, 757
Hypoglycaemia, 103P
Hypokalaemia, 555

Ibuprofen, 483
ICI 118,551, 651P
ICI 169,369, 417
ICI 192605, 710P
ICS 205-930, 663P
Indomethacin, 297S, 483, 870
Indocyanine green, 705P
Infarct, 167S
Influenza, 329
Information booklet, 699P
Inhibitors, 199
Insulin, 103P
Interaction, 27S, 297S, 317S, 323, 469, 475, 789, 795
α-interferon, 795
Inter-subject variability, 781
Intestinal transit, 702P
Intractable epilepsy, 109S
Intragastric activity, 135
Intramyelinic oedema, 43S, 47S, 69S
Intraocular, 599
Intraocular pressure, 69P, 135, 159, 599, 689P
Intravenous, 353, 475
In vitro and *in vivo* hydrolysis, 285
Ionic channel, 757
Ischaemic heart disease, 662P
Isoprenaline infusion, 660P
Itraconazole, 105P

Joint pain, 235

Kallikrein-kinin, 175S
Ketanserin, 122P
Ketorolac, 453
Ketotifen, 88, 116P
Kidney, 13, 811
Kidney excretory function, 151S
Kidney insufficiency, 515
Kinetics, 217S

Labelled insulin, 461
Law, 715
Levodopa, 106P, 123P, 700P
Liability, 715
Lignocaine, 665P
Lipids, 523
Lipoproteins, 851
Lisinopril, 57, 199
Lisuride, 159
Lithium, 648P, 654P, 749
Liver blood flow, 583
Liver damage, 703P
Liver transplant, 631
Long-acting propranolol 80 and 160 mg, 541

Magnesium, 103P
Malaria, 381, 644P, 671P
Malodorous urine, 641, 642
Man, 469
MAO inhibitors, 243
Mastocytosis, 88
Mathematical models, 461
Medifoxamine, 708P
Mefloquine, 381
Melatonin, 649P
Memory, 249S
Menstrual cycle, 681P, 700P
Mental retardation, 113S
Mephenytoin, 622
Metabolism, 205, 391, 636
Metabolites, 205
Metalloproteinase, 133S
Methotrexate, 120P
Methylprednisolone, 285
Metipranolol, 1
Metoprolol, 249S

Mianserin, 445, 825
Midazolam, 631, 636
Migraine, 108P
Mitral valve disease, 661P
Moclobemide, 243, 647P
Monkey, 159S
Monoamine metabolites, 243
Monoaminergic transmission, 695P
Morphine, 377, 499, 515
Morphine-6-glucuronide, 515
Motion sickness, 147
Myelin, 47S
Myocardial, 167S

N-acetylcysteine, 619
N-acetylglutamic acid, 628
Na/K pump, 654P
Narcotic, 377
Natriuresis, 13, 811
Nedocromil sodium, 831
Neural pathways, 831
Neuroendocrine function, 117P
Neuropathology, 43S
Nicardipine, 565, 571, 685P, 704P, 706P
Nicoumalone, 469
Nifedipine, 23, 411, 683P, 706P
Nisoldipine, 583
Nitrendipine, 179, 289S, 411
Nitroglycerin, 653P
N-methylimidazole acetic acid, 88
Non-acetylated salicylates, 609
Non-invasive haemodynamic parameters, 688P
Non-steroidal anti-inflammatory drugs (NSAIDs), 235
Noradrenaline, 7, 555, 805
Normal volunteers, 205

Octanoate, 75
Octreotide, 101P
Oestradiol, 644P
Oestrogen 2-hydroxylase, 644P
Oral, 475
Oral contraception, 851
Org 10172, 39
Oro-caecal transit time, 701P
Orthostatic hypotension, 682P
Osmotic pump, 179
Outpatient monitoring, 215
Over-the-counter drugs, 741
Oxidation phenotype, 387
Oxybuprocaine, 698P

Paracetamol, 262
Parkinsonian patients, 123P
Parkinson's disease, 650P, 682P, 697P
Partition coefficient, 123P
Pemoline, 110P
Performance, 711P
Perindopril, 658P
Perindoprilat, 678P
Peripheral vascular disease, 122P
Peripheral vascular responses, 305
Pharmacodynamic properties, 217S
Pharmacodynamics, 107P, 179, 541, 683P, 685P, 707P
Pharmacogenetics, 435, 491
Pharmacokinetic model, 705P
Pharmacokinetics, 19S, 39, 49, 67, 106P, 112P, 123P, 179P, 181S, 199, 199S, 205, 205S, 211S, 262, 263S, 267S, 283S, 301, 313, 323, 323S, 353, 381, 391, 475, 499, 541, 583, 631, 639, 670P, 671P, 673P, 674P, 678P, 683P, 763, 771, 795, 873
Phenobarbitone, 101P, 645P
Phenotype, 646P
Phenotyping, 223
Phenylephrine, 276, 698P
Phenytoin, 27S, 83, 843
pH monitoring, 135
Pimozide, 110P
Pinacidil, 423
Piroxicam, 704P
Placebo, 19
Placebo-controlled studies, 101S
Plasma concentration, 223, 599
Plasma esterase, 121P
Plasma protein binding, 257
Plasma proteins, 843
Plasma renin activity, 297S
Plasminogen activator, 690P
Platelet aggregation, 122P, 619
Platelet inhibition, 35S
Platelets, 118P
Plethysmography, 757
Poisoning, 92
Polymorphism, 423
Population pharmacokinetics, 57
Population study, 429
Porphyria, 491
Posture, 191
Potassium, 757, 837
Prazosin, 229, 276, 686P
Prednisoline, 116P
Premedication, 377
Prescribing, 367
Prescribing errors, 118P
Prescription information leaflets, 723
Prochlorperazine, 107P, 669P
Progvanil, 781
Prolactin, 243
Propafenone, 435
Propranolol, 229, 309S, 317S, 519, 549, 571, 676P, 763
5-propyl FPA, 675P
Prostacyclin, 119P
Prostaglandin inhibition, 297S
Protein binding, 27S, 229, 519, 665P, 843
Proteins, 73S
Protoporphyria, 703P
Pruritis, 116P
Psychological well-being, 507
Psychomotor, 453
Psychomotor function, 691P
Pulmonary circulation, 165, 405
Pupillary responses, 698P
Pyrimethamine, 381

Quality control, 672P
Quality of life, 235
Quinidine binding, 257

Quinidine, 435
Quinine, 92
Quinine overdosage, 95

Ramipril, 159S
Rapid eye movement sleep, 695P
Rat, 73S, 159S
Raynaud's phenomenon, 119P, 689P
Receptor subtype, 31
Refractory epilepsy, 125S
Regional blood flows, 151S, 167S
Renal blood flow, 167S
Renal failure, 289S, 301
Renal function, 67, 191, 323S
Renal impairment, 275S
Renal transplant patients, 353, 475
Renin, 13, 711
Renin-angiotensin, 175S
Renin-angiotensin system, 191, 305
Renin-inhibitor, 589
Repeated oral charcoal, 95
Respiration, 265
Respiratory depression, 515
Rheumatoid arthritis, 609
RIA, 789
Rilmendine, 687P
R-nicoumalone, 469
RP 42068, 111P

Saccadic eye movements, 712P
Safety, 101S, 125S
Salbutamol, 173, 662, 837
Salicylate, 75
Saliva assays, 507
Saturable elimation, 445
Seasonal variation, 276
Seizure-type, 119S
Selectivity, 555
Self-prescribing, 741
Self-report questionnaires, 507
Serum cortisol, 851
Side effects, 223
Skeletal muscle, 31
Sleep, 110P, 648P
Sleep EEG, 249S
Smooth pursuit movements, 712P
S-nicoumalone, 469
Sodium excretion, 7, 805
Sodium countertransport, 749
Sodium cromoglycate, 88, 710P, 831
Sodium salicylate, 609
Somatic symptoms, 507
Somatosensory evoked potentials, 69S
Somatotropin, 243
Sorbitol, 113P
Spacer, 837
Sparteine, 622
Sparteine oxidation, 272
Spiramycin, 789
Splanchnic vasoconstriction, 225S
Splanchnic haemodynamics, 225S
Stereochemistry, 112P
Stereoisomers, 49
Stereoselective, 519
Stereoselectivity, 469, 825
Stress, 100P
Strontium, 673P
Subcutaneous injection, 461
Sulindac, 657P
Sulphadoxine, 381
Sulpiride, 13
Sustained-release, 565, 599
Sweat glands, 276
Systemic absorption, 1
Systemic haemodynamics, 225S
Systolic time intervals, 343

Tachykinin-induced wheal, 710P
Tacrine hydrochloride, 674P
Terbutaline, 49
Terfenadine, 391
Terguride, 159
Testosterone, 851
Theophylline, 215, 279, 391, 702P, 795
Thiopentone, 693P
Thromboxane receptor antagonist, 710P
Thyroid hormones, 668P
Tiapamil, 696P
Timolol, 1, 429, 698P
Tissue culture, 47S
Toxic neuropathy, 387
Toxicology, 47S
Transdermal application, 653P
Trazodone, 647P
Tremor, 683P
Tremor, essential, 650P
Trimethylamine, 423
Tropicamide, 698P
Tubular excretion, 291
Tumour necrosis factor, 257

UK-52,046, 102P, 679P, 680P, 683P, 686P
Umbilical artery, 109P

Vacuolation, 53S
Valproate, 843
Valproic acid, 323
Variability, 585
Vascular smooth muscle, 757
Vasodilatation, 139
Vasodilator, 549
Vasodilator agents, 165, 405
Venous reflex response, 19
Verapamil, 706P
Vigabatrin, 13S, 19S, 23S, 27S, 35S, 43S, 47S, 53S, 61S, 69S, 73S, 87S, 95S, 101S, 109S, 113S, 119S, 125S
Volunteers, 75, 199S, 343, 453, 715
Volunteer studies, 125

Wheal, 870

Zofenopril, 371
Zy15109, 628